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Protein Disulfide Isomerase-like protein of the Testis (PDILT) is an endoplasmic reticulum 
(ER) protein that is required for male fertility and is a member of the Protein Disulfide 
Isomerase (PDI) family. PDI has a well-established role in the formation of disulfide bonds in 
newly synthesised proteins, which is facilitated by thioredoxin active sites (a CXXC motif) in 
the a domains. PDILT, however, lacks these classic redox active sites and has an SXXS and a 
SXXC motif in the a and a’ domain respectively but nevertheless interacts with clients in the 
ER. PDILT also contains a unique C-terminal extension, the function of which is unknown. 
In order to examine the role that the unique structural elements of PDILT contribute to 
client binding, several PDILT mutant constructs were transfected into HT1080 cells and 
subjected to a series of western blotting and immunofluorescence experiments. In this 
thesis, data is shown to support the assertion that the two solvent-exposed cysteines 
present in PDILT mediate all disulphide dependent interactions with client proteins. We also 
show that the deletion of the C-terminal extension caused a large increase in client 
interactions and thus we theorise that the tail of PDILT regulates PDILT/client protein 
interactions.  
PDILT is specifically expressed in the post-meiotic spermatid cells of the testis, which limits 
the potential to study the expression and function of endogenous PDILT in cell lines. Thus, 
work in this thesis has also examined a variety of immortalised cell lines for PDILT 
expression, to develop better systems for the further study of testis specific chaperones. 
Along with PDILT, a range of immortalised cell lines were also examined for the 
derepression of other testis specific ER chaperone proteins. As a result of this investigation, 
this thesis also reports on the unique expression of calmegin in cell lines with different 
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1.1. The Endoplasmic Reticulum 
The endoplasmic reticulum (ER) ensures that secreted or secretory pathway proteins 
produced by the cell are correctly folded and modified. The ER facilitates this folding of 
newly synthesised proteins at several different levels. The first level of screening comes from 
general error checking by a series of major molecular chaperones. These chaperone 
proteins, such as BiP/GRp78 are able to detect obvious defects in protein folding, such as the 
expose of hydrophobic areas. Once the defects have been detected, these proteins are able 
to facilitate refolding of the protein to its correct shape and also stops the protein from 
being secreted. A secondary level of error checking is also present in the ER, but is much 
more specific than the previous level and checks specific protein families. In a similar fashion 
to the previous level of error checking, the binding and activity of these proteins prevents 
export of the client proteins. The ER also contains a complex sorting system that is able to 
separate proteins according to their folding state, with correctly folded proteins being 
localised to specific areas for export and incorrectly folded proteins being targeted for 
degradation via ER-associated degradation (ERAD) (Ellgaard and Helenius 2001).  This quality 
control system  is designed to ensure that only correctly folded proteins can exit the ER and 
any incorrectly folded proteins are destroyed before they can aggregate and cause damage 
to the cell (Ellgaard, Helenius 2001).  
Protein disulfide isomerase (PDI) and its homologues have been identified as key proteins 
involved in the protein folding process. PDI catalyses the formation of disulphide bonds in 
newly synthesized proteins, but can also work as a general chaperone. PDILT is a relatively 
newly identified homologue of the PDI family, and was cloned by van Lith et al. 2004. PDILT 
has been found to localise to the testis and is required for male fertility.  
1.2. The PDI Family of Proteins 
One of the many folding mechanisms used to stabilise protein structure is the formation of 
disulphide bonds. PDI is a key protein involved in this process. This abundant 55 kDa protein 
has two main roles, namely oxidation/reduction, and the isomerisation of disulfide bonds in 
nascent proteins. PDI is a member of the thioredoxin superfamily but has several family 
members in humans, with these family members summarised in Table 1.  PDIs and other 
members of the thioredoxin superfamily are characterised by having a CXXC motif in the  
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active site. PDI contains this classical thioredoxin active site within its a and a’ domain. The 
protein also contains two other domains, the b and b’ domains, that are catalytically 
inactive. A diagrammatic representative of PDIs structure is presented in Figure 1. PDI has 
several mammalian homologues that are localised to the ER, all of which have slight 
variations in structure but all contain at least one thioredoxin-like domain (Benham et al. 
2013). 
 
1.3. PDI Key Functions  
The oxidation/reduction activity of PDI relies on the active site being able to exist in two 
forms, an oxidised form or a reduced form. The oxidised form is when the cysteines in each 
active site are linked via a disulfide bond and the reduced state is when the cysteines exist in 
a dithiol state. PDI is able to cycle between these two states by being oxidised and reduced 
and in doing so, can oxidise or reduce other substrates, breaking or forming disulphide 
bonds. The process of disulphide bond formation occurs by a redox pathway, which is 
summarised in Figure 2. It can be seen in Figure 2 that the Ero1α protein plays a key role in 
this cycling of oxidation and reduction that ultimately leads to disulphide bond formation. 
Ero1α is able to donate disulphide bonds to PDI, which then allows PDI to induce disulphide 
bond formation in client proteins. This however causes electron flow in the opposite 
direction, where an electron passes from PDI to Ero1α to molecular oxygen. Via utilising the 
FAD cofactor, molecular oxygen is reduced to peroxide, which is processed within the ER via 
peroxiredoxin IV, which acts to detoxify the molecule (Szarka and Bánhegyi 2011).  
The process of disulphide formation can be error prone, due to the multiple ways cysteines 
can be disulfide-bonded within the same protein, as can be seen in Figure 3. As a result, 
these bonds often need to be corrected and PDI has isomerisation activity that facilitates 
these corrections. PDI is able to do this via one of two routes; the intramolecular route, or 
via cycles of oxidation and reduction. The intramolecular route allows PDI to directly attack a 
target cysteine and disrupt the disulphide bond it has formed. The bonds within the protein 
can then be rearranged or be reformed. The second route is via a repeated cycle of oxidation 
and reduction of the substrate that causes random rearrangement of the disulphide bonds 
until the correct protein structure is formed. These two routes allow for PDI to mediate the 





Figure 1. The Domain Organisation of PDI. A diagrammatic representation of the domain 














Table 1: The Mammalian Protein Disulphide Isomerase Family 
Name of Protein Domain Arrangement Active Site Sequence Protein Length 
PDI (PDIA1) abb′xa CGHC, CGHC 508 
PDIp (PDIA2) abb'xa CGHC, CTHC 525 
ERp57 (PDIA3) abb'xa CGHC, CGHC 505 
ERp72 (PDIA4) aoabb′xa′ CGHC. CGHC, CGHC 645 
PDIR (PDIA5) baoaa′ CSMC, CGHC, CPHC 519 
P5 (PDIA6) aa’b CGHC, CGHC 440 
PDILT abb’xa’ SKQS, SKKC 584 
ERdJ5 Jabbaaa CSHC, CPPC, CHPC, CGPC 793 
ERp44 abb’ CRFS 406 
ERp46 ao aa′ CGHC, CGHC, CGHC 432 
ERp18 a CGAC 172 
ERp27 bb’ - 273 
ERp29 b’D - 261 
TMX a CPAC 280 
TMX2 a SNDC 296 
TMX3 abb’ CGHC 454 
TMX4 a CPSC 349 
hAGR2 a CPHS 175 
hAGR3 a CQYS 166 
ERp90 Trz1-5 - 825 
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Figure 3. Intra-molecular Disulphide Bond Rearrangement. A diagrammatic representation 
of the many different configurations of disulphide bonds that are possible within the same 
protein, showing the need for PDIs isomerisation activity to ensure the correct configuration 
of disulphide bonds form.  
Figure 2. The Process of Oxidation and Isomerisation Mediated by PDI. (A) The process of 
oxidation that leads to the formation of disulphide bonds in newly formed proteins. (B) The 
process of isomerisation that allows PDILT to break incorrectly formed disulphide bonds in 



































1.4. PDI Additional Functions 
PDI performs a number of other functions in the ER. It has been shown that the β subunit of 
the enzyme prolyl-4-hydroxylase is PDI, which facilitates the hydroxylation of collagen.  PDI 
has also been reported to have chaperone activity on non-disulfide containing proteins, as it 
has been shown that when GAPDH, a protein that contains no disulphide bonds, is incubated 
with PDI, this increases reactivation of GAPDH and decreases its aggregation. (Cai et al. 
1994). 
1.5. PDILT Discovery  
Whilst PDI has been studied to a great extent, homologues of this protein are less well 
investigated. These homologues include PDIp, which has been found to be specifically 
localised to the pancreas, and EndoPDI, which specifically localises to endothelium tissue. 
PDILT, another PDI homologue, was discovered using a database-BLAST search approach, 
with PDI as the input sequence (van Lith et al. 2004). The PDILT gene was initially termed 
GI28/21, which shared 27 % identity and 48 % similarity with PDI. The protein encoded by 
this gene has an unusual abb’a’ domain arrangement, but lacks the redox active motifs 
(CXXC), instead having SSKQS (SXXS) and WSKKC (SXXC) in the a and a’ domains respectively. 
In addition to this difference, GI28/21 also has a free cysteine at position 135 and both N 
and C-terminals are altered compared to PDI. The N-terminus has a small insertion and the C 
terminus has an extension that increases the size of this protein to 67 kD (van Lith et al. 
2004). 
1.6. PDILT Expression and Localisation  
The expression and localisation of this unusual protein was then examined (van Lith et al. 
2004). This was achieved by RT-PCR, western blotting and immunohistochemistry using 
several different mouse tissues. The only tissue that returned a positive identification of 
GI28/21 was mouse testis tissue. Several human tissue lines were also analysed with none 
showing GI28/21 expression. Analysis of testis derived Sertoli SK11 cells also showed they 
did not express GI28/21. With this expression data, the protein was renamed protein 
disulfide isomerase like protein of the testis (PDILT). As no cell lines to date express PDILT 
endogenously, Myc tagged PDILT constructs were transfected into HeLa cells to study its 
intracellular localisation. Immunostaining and confocal microscopy revealed PDI and PDILT 
had overlapping staining, indicating that PDILT resides in the ER. To determine the 
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glycosylation state of PDILT and provide further evidence of its localisation, a PDILT 
transfected cell lysate was subject to treatment with Endoglycosidase H (Endo H), which can 
only digest immature N-glycans in the ER. When subject to western blotting, PDILT increased 
mobility, moving from 76 kD to 65 kD after Endo H digestion. These results prove that PDILT 
is an ER resident glycosylated protein. The work by van Lith et al. 2007 defined the cell-
specific location of PDILT within the testis. This was done by immunohistochemistry of 
sections of testis derived from rat, mouse, human, marmoset and macaque. It was found 
that in rat, mouse and macaque seminiferous tubule sections, the germ cells were heavily 
stained. The other tissues, human and marmoset, had more complex staining but within 
similar testis cell areas. This specific expression pattern is unique, in comparison to other PDI 
homologues, which have been shown to have broad expression across all cell types within 
the testis. 
The germ cells that show expression of PDILT were found to be at stage VII of maturation, 
which marks when the germ cells begin to differentiate. All species were found to express 
PDILT once the meiotic division had occurred. This observation, combined with the 
observation that PDILT was not present in spermatozoa, led to the hypothesis that PDILT 
was linked to germ cell development and that its expression was temporally controlled. To 
test this, testis tissues from rodents at different ages were subject to RT-PCR to test for 
PDILT expression. PDILT mRNA wasn’t detected in the testis until 30 days of age, and had 
maximum expression by day 45. Interestingly, when the testis was examined for the 
expression of the testis-specific ER resident chaperone calmegin (CLGN), it was found to 
overlap with the appearance of PDILT in the testis. To determine whether the onset of 
protein expression mirrored the onset of gene expression, western blotting was performed. 
It was found that the PDILT protein appeared at day 30 and reached the maximum by day 
45, whilst CLGN reached maximum expression from day 30. This was confirmed with 
immunostaining of testis sections taken from rodents at different ages, which showed that 
PDILT positive germ cells only appeared at day 31 in the seminiferous tubules. These results 
taken together show that PDILT expression is tied to the formation of round spermatids 
(stage VII) and is also co-ordinated with the expression of CLGN (van Lith et al. 2007). 
1.7. PDILT Activity  
It has been well documented that PDI forms disulfide bonds with both client and partner 
proteins as part of its oxidative cycle, so to establish whether PDILT forms similar complexes, 
pulse-chase and western blotting experiments were carried out under reducing and non-
reducing conditions on cells transfected with PDILT. Under non-reducing conditions, it was 
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shown that higher molecular weight complexes do form, suggesting that PDILT does interact 
with other proteins. The identity of these proteins remains unknown, although one of these 
complexes is likely to be a PDILT dimer. Comparison between the reducing and non-reducing 
gels showed that the monomeric form of PDILT doesn’t form a disulphide bond between the 
SXXC motif in the a’ domain and non-active cysteine at position 135, as no difference in 
mobility was detected upon western blotting. Both of these observations were found to be 
true in vivo, as PDILT from mouse testis lysate showed a similar banding pattern. To 
determine the roles of the conserved free cysteines in PDILT, van Lith et al. 2007 transfected 
cell lines with PDILT mutants (C135A, C420A and the C135A/C420A double mutant) and 
analysed transfectant lysates on a western blot, under reducing and non-reducing 
conditions, to see if these cysteines were required for complex formation. Both of the single 
substitution PDILT mutants caused a reduction in the molecular weight of the higher 
molecular weight complexes and the double mutant abolished all interactions, indicating 
that both cysteines are solvent exposed and involved in protein interactions (van Lith et al. 
2007). 
In order to see if PDILT shared any other similar interactions with PDI, it was then 
investigated if PDILT could also interact with Ero1α, as this would help establish whether 
redox activity is required for a PDI protein to interact with an Ero1 protein. Co-
immunoprecipitation of transfected Ero1a and PDI did show that they could interact, 
although such an interaction may not occur functionally in vivo. To examine whether PDILT 
had any oxido-reductase activity in vitro, an insulin reduction assay was used. Incubating 
insulin with PDI and PDILT, respectively, and comparing whether the insulin B chain 
precipitates is indicative of reductase activity. For PDI the insulin B chain precipitated out, as 
expected from previous studies (Watanabe et al. 2014). In contrast, PDILT did not catalyse 
the reduction of insulin, suggesting that PDILT does not have classical oxidoreductase 
activities. 
The crystal structure of PDILT has now been solved. Initially, only the b’ domain of PDILT was 
crystallised, which revealed the presence of a hydrophobic pocket, which is likely the site of 
substrate binding (Bastos-Aristizabal et al. 2014). However, in 2017, the crystal structure of 
full-length PDILT was solved to a 2.4 Å resolution. This structure confirmed the observation 
of a hydrophobic pocket in the b’ domain but also provided evidence that the C terminal tail 




1.8. PDILT and Male Fertility  
One study, Ellerman et al. 2006, has the PDI family to the mechanism of sperm/egg 
membrane fusion, showing that a variety of PDI inhibitors reduced both fertilisation rate and 
fertilisation index. This paper suggested that ERp57 could operate at the sperm cell surface 
to provide oxido-reductase activity for sperm adhesion proteins. However, the inhibitors and 
antibodies used in these experiments were not specific to ERp57, and it remains possible 
that other oxido-reductase activities are required for sperm-egg binding. Since PDILT is 
present within the testis, and is not thought to be present in the sperm, it is unlikely to have 
the same role as ERp57. How PDILT links to male fertility was indicated in a study of CLGN 
and calsperin (CALR3), which are germ cell specific homologues of ER resident lectin 
chaperones. These two proteins assist the maturation of a select group of ADAMs, key 
proteins in male fertility that are required for correct sperm migration and sperm egg 
adhesion. CLGN itself is required for the dimerization of ADAM1A/ADAM2 and CALR3 is 
required for the maturation of ADAM3. PDILT interacts with both CLGN (van Lith et al. 2007) 
and CALR3 (Tokuhiro et al. 2012), indicating that these chaperones work together in male 
fertility. Proof of these interactions was found by subjecting testis and liver lysates to 
immunoprecipitation with either an anti-CLGN or an anti-PDILT antibody, with the resulting 
lysate being analysed by western blotting and stained for co-immunoprecipitating CLGN and 
PDILT. Both immunoprecipitated lysates contained CLGN and PDILT, showing that PDILT does 
interact with CLGN. Further work showed that PDILT interacted with CLGN and CALR3 and 
that it interacted with ADAM3 but not ADAM1/2 via a series of immunoprecipitation and 
western blot experiments. In tissue from Pdilt-/- male mice, it was noted that whilst 
ADAM1/2 heterodimerization was still present, ADAM 3 disappeared from spermatozoa 
when PDILT was knocked out. To try and explain this, testis and epididymal cell lysates were 
subject to western blotting and it was noted that ADAM3 was present on maturing sperm 
cells until the caput epididymis, suggesting that lack of PDILT causes loss of ADAM3 from the 
spermatozoa at a late stage of maturation (Tokuhiro et al. 2012). 
To further explore the impact of these specialised ER chaperone proteins on Adam3 
maturation, several knock out mice were analysed. These knockout mice had their Pdilt, Clgn 
and Calr3 genes disrupted. A trypsin digest was then performed on mutant spermatozoa 
isolated from these knockout mice, to see which Adam proteins were expressed on the 
surface membrane. Whilst sperm from wild type and Clgn-/- had both Adam2 and Adam3 
proteins on their surface, it was found that Calr3-/- and Pdilt-/- spermatozoa both lacked 
Adam3 on their surface. It was then asked whether Clgn, Calr3 and Pdilt participated in the 
9 
 
folding of Adam3. To do this wt, Clgn-/-, Calr3-/- and Pdilt-/- spermatogenic cell membrane 
proteins were separated into detergent depleted or enriched samples and run on SDS-PAGE 
under reducing or non-reducing conditions. Under non-reducing conditions, the Adam3 
protein was in a doublet, with the compact oxidised form being strongest in wt and Clgn-/- 
tissue but far weaker in the Calr3-/- and the Pdilt-/- mutants, thus suggesting that Pdilt and 
Calr3 have a role in the oxidative folding of Adam3 disulphide bonds. Whilst this shows clear 
evidence of Pdilts involvement in the maturation of Adam3, it did not demonstrate direct 
oxidoreductase activity. The consequence of a lack of Pdilt is male infertility, as when both 
male and female Pdilt-/- mice were mated with wt partners, only the males presented with 
infertility. To explore this observation further, green florescent protein was inserted 
transgenically into Pdilt-/- sperm and the sperm observed post-mating in the female 
reproductive tract, where they failed to enter the oviduct, despite showing normal mobility. 
This issue could be bypassed by inserting capacitated spermatozoa directly into the oviduct, 
which allowed for the production of healthy offspring. Interestingly, when Pdilt-/- 
spermatozoa were added to cumulus-free ZP-intact eggs, it was found that the spermatozoa 
had a low binding rate. However, fertilisation could be achieved with these mutant 
spermatozoa in the presence of cumulus conditioned media or with cumulus-free eggs. Thus 
cumulus cells have a previously under-estimated role in fertility and the factor(s) that help 
sperm bypass the requirement for Pdilt have yet to be identified (Tokuhiro et al. 2012). 
1.9. PDILT Beyond the Testis 
The impact PDILT has on male fertility has been extensively studied but there are hints that 
PDILT may be expressed beyond the male germ cells. For example, PDILT has been detected 
in seminiferous fluid (C. Avellar, personal communication) and has been identified as a 
genetic variant in a meta-analysis of factors that influence uromodulin expression, 
suggesting that PDILT may be expressed by specialist kidney cells (Olden et al. 2014). PDILT 
also becomes derepressed in patients with the rare autoimmune disease Autoimmune 
polyendocrine syndrome type 1 (APS1) (Landegren et al. 2016). Observation of data held at 
the Human Protein Atlas also suggests that PDILT may be expressed in certain pathologies, 
including in melanomas (https://www.proteinatlas.org). This is based on staining with a 
PDILT antibody (Sigma-Aldrich HPA041913) that has yet to be validated, and may potentially 
cross react with other PDI proteins. The Human Protein Atlas is a Swedish project that began 
in 2003 with the aim of mapping all known human proteins to their tissue of origin. One of 
the arms of this project is to analyse protein expression levels in cancer. When this project 
investigated a variety of cancer tissues for PDILT using the PDILT antibody (Sigma-Aldrich 
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HPA041913), there was some immunoreactivity in the cytoplasmic and nuclear 
compartment of several cancers, with some of the largest immunoreactivity found in 
melanoma. This suggestion that PDILT might be found in certain cancers leads to the 
possibility that PDILT may provide a growth advantage or promote metastatic activity of 
those tumours. This possibility is realistic, as numerous studies have found that that ER 
stress and ER proteins play an active role in the maintenance and development of cancer, as 
discussed below.  
1.10. Cancer and ER Stress 
The connection between the ER and pathology has been well researched, as many 
pathological conditions are known to cause disruption to the normal functioning of the ER, 
such as Alzheimer’s disease, Type 2 Diabetes and a variety of cancers (Ozcan and Tabas 
2012). How this deregulation occurs is different in different pathologies, but there are 
ultimately three ways pathologies are able to effect the ER. The first is via increasing the 
expression of key ER proteins, such as the increased expression of GRP 78/BiP and GRP94 
observed in breast, lung and colon cancers (Moenner et al. 2007). Another effect is via 
changing post-translational modifications on ER proteins, such as the selective cleavage of 
PC1 and PC2 convertases, deregulating these proteases in liver metastasis (Tzimas et al. 
2005). Finally, some pathologies are able to induce ER proteins that are normally localised 
solely to the ER to become secreted, such as the identification of Calreticulin in 
hepatocellular carcinoma patients (Le Naour et al. 2002). This alteration of the normal 
functioning of the ER can be expected in cancer. The ability of the cancer cell to manage ER 
homeostasis is key to its survival, as a failure in ER processing can lead to triggering of the 
unfolded protein response (UPR), which can ultimately lead to cell death by apoptosis. The 
and nutrient starved conditions often seen in cancer microenvironments can lead to ER 
stress. Thus the ability of a cancer to manage ER stress and the UPR is vital to ensure the 
survival of the cancer cell (Moenner et al. 2007).  
The UPR is mediated by three proximal sensors: PERK, ATF6 and Ire1. How these proximal 
sensors trigger the UPR is depicted in Figure 4. PERK is a serine threonine kinase and acts to 
reduce the load of unfolded proteins in the ER. It stops the general translation of proteins, 
which otherwise would enter the ER and add to the aggregation of unfolded proteins. 
Interestingly, when a dominant negative PERK was forcibly expressed in MEF cells, these 
cells became more likely to die from hypoxic stress, suggesting that cells use PERK as survival 
signal to maintain normal function during times of cell stress (Meixia et al. 2005). The second 
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proximal signal is IRE1, which upon dimerization and phosphorylation causes the splicing of 
the XPB1 mRNA, which then leads to the production of the XBP1 protein. XBP1 then 
activates UPR linked target genes. Similar to PERK, when expression of IRE1 is silenced in a 
variety of cells, these cells are sensitised to death by hypoxia compared to wild type cells. 
This demonstrates the importance of this protein in determining the outcome of ER stress. 
The final proximal sensor is ATF6, which upon activation and translocation to the Golgi is 
cleaved by two related proteases, S1P and S2P. The release of a cytosolic fragment of ATF6 
with transcription factor activity causes the activation of key genes involved in managing ER 













































Figure 4. Signalling Pathways that Trigger the UPR. (A) Summary of the IRE1α signalling 




The significance of these proteins in managing ER stress, shown by how easily cells can be 
pushed into apoptosis when these proteins are absent, demonstrates how this protein 
machinery can be exploited by cancer as a survival mechanism. UPR transcription factors, 
specifically AFT6 and XBP-1, have been found to be upregulated in hepatocellular carcinoma 
and is likely to be a protective response (Masahiro et al. 2003). Interestingly, these aren’t 
the only proteins linked to the ER to undergo upregulation upon the development of cancer. 
Two more examples are GRP170 and ERp29. ERp29 is a small member of the PDI family 
whereas GRP170 is an ATPase which is normally involved in the release of VEGF, a protein 
that stimulates angiogenesis. The upregulation of GRP170 by cancer is used to ensure the 
complete protein folding and secretion of VEGF, as a mechanism of re-establishing a blood 
supply (Ozawa et al. 2001).  
Whilst PDILT has never been examined at the molecular level to see if it is upregulated in 
cancer, other members of the PDI family, in addition to ERp57, have been widely studied 
and have been found to play key roles in cancer progression (Samanta et al. 2017). 
1.11. The PDI Family and Cancer 
Of all the members of the PDI family, AGR2 probably has the strongest relationship to cancer 
development. AGR2 was originally identified in Xenopus laevis and has strong expression in 
endoderm derived organs, especially in mucus producing and secreting cells. Indeed, the 
Agr2-/- mouse is deficient in mucus production and is susceptible to gastro-intestinal disease 
because of a defect in mucin quality control (Park et al. 2009). AGR2s role in cancer has been 
studied in a number of systems. Clonogenic assays performed on a variety of breast cancer 
cell lines have shown that the expression of AGR2 increased cancer cell survival and did not 
inhibit cell growth (Hrstka et al. 2010). Silencing AGR2 also inhibited invasion, proliferation 
and survival of breast cancer cell lines.  
One of the mechanisms by which cancers utilise ER proteins for survival is by inducing 
resistance to classical cancer treatments. An example of this comes from breast cancer, 
where the AGR2 promotor is activated by oestrogen. This then leads to resistance of breast 
cancer cells to the classical treatment tamoxifen, as this treatment induces pro-survival 
genes. To understand which genes were being induced, a proteomic study of genes 
upregulated upon tamoxifen treatment was conducted. It found AGR2 to be the second 
highest induced protein. A chromatin immunoprecipitation analysis confirmed the activation 
of AGR2 by tamoxifen, as elevated levels of the alpha oestrogen receptor were found bound 
to the promoter of ARG2 when in the presence of tamoxifen, showing that it is induced by 
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cancer as a survival mechanism (Chevet et al. 2013). AGR2 has also been shown to play an 
important role in oesophageal cancer, as it was found to be significantly upregulated during 
the metaplastic epithelium stage of oesophageal cancer progression. It was then found that 
AGR2 acts to inhibit p53, an important cancer inhibitory protein (Chevet et al. 2013). These 
two specific examples demonstrate that AGR2 is strongly upregulated during the 
development of particular cancers. The exact mechanisms that allow AGR2 to support 
cancer growth are unknown, but it has been suggested that AGR2 ensures the correct 
processing of newly synthesised proteins, preventing the UPR response and thus preventing 
self-induced cell death (Higa et al. 2011).  
AGR2 may contribute to the shift of a cancer to metastasis. One of the clearest examples is 
that grafted cancers that overexpress AGR2 have a higher likelihood to metastasize, when 
transplanted into nude mice models. The molecular mechanism of how AGR2 decreased the 
adhesion and increased the invasion of cancer cells was studied in pancreatic ductal 
adenocarcinoma. The expression of AGR2 was present across all stages of tumour 
development, and was localised both to the cytoplasm and at the surface of the cell 
membrane. The finding that AGR2 can be localised to the surface of the cell concurs with 
observations in breast cancer. By comparing two cell lines, one that overexpresses AGR2 and 
one subject to AGR2 silencing, AGR2s effect on metastasis could be studied. As expected, 
the cell line with upregulated AGR2 had an increased rate of invasion and the cell line with 
silenced AGR2 had a reduced rate of invasion. The key genetic finding of this study was that 
the proteases Cathepsin B (CTSB) and Cathepsin D (CTSD) were upregulated, which are 
proteases linked to highly invasive cancer. These observations show that AGR2 also has a 
role in cell migration and adhesion, as well as the role in maintaining ER health (Dumartin et 
al. 2011). 
AGR2 isn’t the only PDI family member that has been linked to invasiveness of a cancer cell. 
PDIA6 (P5), an aa’b redox active PDI homolog, was also studied in relation to glioblastoma 
multiforme (Goplen et al. 2006). Glioblastoma multiforme is another highly aggressive 
cancer that kills patients, typically within a year. Because of this hyper-aggressiveness, 
identifying genetic markers which determine aggressiveness is key to patient management 
and treatment. In order to identify these markers, an unusual xenotransplantation model of 
glioblastoma was established. It was noted that cancer spheroids on their initial 
transplantation into the CNS of nude mice had a phenotype with high invasiveness and low 
angiogenesis but when serially transplanted into nude mice, switched phenotype and were 
found to have low invasiveness with a high level of angiogenesis. These two phenotypic 
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qualities allow for a comparison between cancer cells from the same donor. The upregulated 
proteins from each phenotype were subject to mass spectrometry and identified. PDIA6 was 
one of the proteins identified in both phenotypes, but was found to have expression 
throughout the whole of the tumour in the highly invasive phenotype and only at the 
periphery in the low invasive phenotype. PDIA6 was also found at the surface of the cell 
using flow cytometry. Thus it is possible that PDIA6 acts at the cell surface to encourage cell 
migration. To investigate this, a PDI inhibitor was applied to both types of spheroid. This 
caused a decrease in invasive behaviour. The study went on to suggest that PDI acts at the 
cell surface by altering the conformational form of β3 integrin, as when this adhesion 
protein was blocked by an antibody, it also caused a reduction in invasive behaviour (Goplen 
et al. 2006).  
Numerous studies show a clear correlation between higher expression of members of the 
PDI family and cancer (Samanta et al. 2017). Not only has it been demonstrated that they 
are upregulated to maintain ER integrity and stop UPR proapoptotic signalling (Higa et al. 
2011), it has also been shown to play an active role at the surface of the cell, in reducing cell 
adhesion and promoting tumour migration (Dumartin et al. 2011). Thus, PDILT should also 
be considered as a candidate protein that is subject to upregulation via cancer mechanisms 
as a way to ensure tumour survival and invasion.  
1.12. The PDI Family as a Target for Cancer Treatment 
Whether targeting PDI can be effective in cancer treatment was explored in Lovat et al. 
2008. This study explored the theory that cancer cells can be pushed into apoptosis by 
inhibition of PDI, as this leads to increased ER stress and UPR induced apoptosis. Firstly, the 
study demonstrated that ER stress could be induced in a variety of human melanoma cell 
lines with Fenretinide and Bortezomib. Fenretinide acts to induce ER stress through the 
generation of reactive oxygen species (ROS) (Mody and Mcilroy 2014) and Bortezomib acts 
to induce ER stress through inhibiting the proteasome, causing an aggregation of misfolded 
proteins within the ER, ultimately causing ER stress (Nawrocki et al. 2005). When ER stress 
had been validated, the impact of bacitracin, a PDI inhibitor, was investigated. It was found 
that when bacitracin was the only chemical incubated with the melanoma cell lines it didn’t 
increase apoptosis of the melanoma cells. However, when bacitracin was incubated with 
Fenretinide or Bortezomib, there was an increase in cell death by apoptosis. This showed 
that when melanoma cells experience ER stress, they can be driven into apoptosis by 
inhibiting key ER proteins, in this case, PDI. To prove that bacitracin inhibition of PDI was the 
cause of the increase in cell death, P4HB (gene name of PDI) was transfected into the 
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melanoma cell lines, either in a redox active from or in a redox inactive form. Exogenous PDI 
prevented the increased cell death observed when bacitracin was incubated with either 
Fenretinide or Bortezomib. This is likely caused by the transfected PDI competing for binding 
to bacitracin, allowing PDI to facilitate cell survival. This effect was not seen when the 
inactive PDI was transfected into the melanoma cell lines. This highlights the importance of 
PDI in cancer cell survival during ER stress and also demonstrates that targeting PDI can have 
therapeutic potential (Lovat et al. 2008).  
Although the full mechanistic detail of PDI family function in cancer is incomplete, clinical 
investigations into the link between PDI and cancer have been undertaken. An analysis 
carried out on published microarray data found that, compared to normal tissue, PDI is 
significantly upregulated in a number of cancers, such as lymphoma, ovarian and prostate 
cancers. PDI has also been found to be associated with the development of drug resistance 
during cancer treatment. For example, comparison of Aplidin resistant HeLa-R to Aplidin 
sensitive cells shows Aplidin resistant cells have a much higher level of PDI expression. When 
PDI is inhibited by direct treatment, the cells become re-sensitised to the treatment. PDI has 
also been linked to the maintenance of cancer cells. Several synthetic compounds have also 
been developed as inhibitors of PDI, with a view to using them in cancer treatment. These 
include Propynoic Acid Carbamoyl Methyl Amides (PACMA 31), an irreversible inhibitor of 
PDI, and 16F1, which targets both PDIA1 and PDIA3 (Xu et al. 2014). 
Combining this knowledge with the observation from the Human Protein Atlas that PDILT is 
possibly expressed in melanoma tissue and that disrupting PDI expression in the ER has 
therapeutic potential, the expression of PDILT in melanoma should be further investigated 
to evaluate if it is also facilitating cancer cell survival. This would also open up the possibility 
for targeting PDILT therapeutically as a potential treatment. 
1.13. Thesis Aims  
The aims of this thesis are as follows: 
• To investigate which structural features are required for PDILT to interact with 
partner proteins. This will be done by analysing how key mutations impact on PDILTs 
ability to interact with client proteins. 
• To explore the expression of PDILT in melanoma cell lines using a range of 




The hypothesis of this thesis is: 
• That solvent exposed cysteine residues are required for PDILT to interact with client 
proteins. 
• That the C terminal tail of PDILT is required for interactions between PDILT and at 
least some partner or client proteins. 




















2. Materials and Methods 
2.1 Cell Culture 
The human fibrosarcoma HT1080 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(Gibco, ThermoFischer Scientific), which was supplemented with a combination of 2 mM 
glutamax (Gibco, ThermoFischer Scientific), 100 units/ml penicillin (Gibco, ThermoFischer), 
100 μg/ml mM streptomycin (Gibco, ThermoFischer) and 8 % of fetal bovine serum (Sigma). 
All melanoma cell lines were mycoplasma-free and were kindly donated by Prof Lovat 
(Institute of Cellular Biology, Newcastle University). These cell lines were A375, WM35, 
C8161, WM1641, WM164, SKMEL28 and CHL1. All these cell lines were cultured in 
Dulbecco’s Modified Eagle’s Medium (Gibco, ThermoFischer Scientific), which was 
supplemented with a combination of 2 mM glutamax (Gibco, ThermoFischer Scientific), 100 
units/ml penicillin (Gibco, ThermoFischer), 100 μg/ml streptomycin (Gibco, ThermoFischer) 
and  8 % fetal calf serum (Sigma). All cell lines were passaged when 70-90 % confluent using 
1 ml 0.05 % trypsin (Gibco, ThermoFischer Scientific) to disrupt the cell monolayer, after 
which cells were washed three times with 5-10 ml of PBS (Sigma). All cell lines were cultured 
in an incubator kept at 37˚C and 5 % CO2. Cell lines were tested for mycoplasma in house by 
DAPI staining followed by immunofluorescence, examining for contaminating DNA. The cell 
lines donated from Prof P. Lovat’s group were tested for mycoplasma before being gifted to 
our laboratory. 
 
2.2 Spheroid Culture      
Melanoma spheroids were prepared by adding a 5000 melanoma cell suspension in 200 μl of 
Dulbecco’s Modified Eagle’s Medium (Gibco, ThermoFischer Scientific) to a 1.5 % noble agar-
lined (Sigma) well of a 96 well plate. A 5000 cell suspension was produced by counting a cell 
suspension solution using a haemocytometer (Improved Neubauer) and then diluted. The 
resultant cell suspensions were left to incubate for 4, 6 or 8 days at 37˚C and 5 % CO2, to 
mimic physiological conditions in vivo. Over this incubation time the melanoma cells formed 
into spheroids. Spheroids were collected from each well, at the relevant time point, using a 
P1000 pipette and then decanted into a 1.5 ml Eppendorf tube. When the 10 spheroids were 
harvested, the excess media was then drained from the Eppendorf. The collected spheroids 
were then either lysed with MNT lysis buffer (20 mM MES, 30 mM Tris, 100 mM NaCl, pH 
7.4), for western blotting analysis or prepared for immunofluorescence. Spheroids were 
prepared for immunofluorescence by adding 4 % paraformaldehyde (VWR Chemicals), 
diluted in PBS, and allowing the spheroids to fix for 2 hours. Once fixed, the spheroids were 
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suspended in 5 % agarose (Sigma) and transferred to a 50 ml falcon tube. Once the agarose 
had solidified it was taken out of the falcon tube and transferred to a histology cassette. The 
resultant cassette was sent to be imbedded in paraffin by the Histology Department of the 
Royal Victoria Infirmary, Newcastle.  
 
2.3 Cell Lysis 
Cells were lysed either once confluent in a 6 cm dish or 24-48 hours post transfection. 6 cm 
dishes were washed twice in PBS and then transferred to an ice cooled metal tray coated in 
tissue soaked with ethanol. 300 μl of lysis buffer (1×Triton x100, 1x MNT (20 mM MES, 30 
mM Tris-HCL, 100 mM NaCl, pH 7.4) and 1 μg/ml of a protease inhibitor cocktail comprised 
of cystatin, leupeptin, antipain, pepstatin A (CLAP)) was applied to the dish and scraped with 
a cell scraper. The resultant lysate was transferred to a 1.5 ml Eppendorf. SD rat testis tissue 
was lysed in 1 ml of lysis buffer and subjected to grinding with a pestle and mortar. The 
resultant lysate was transferred to a 1.5 ml Eppendorf tube. Two frozen melanocyte cell 
pellets were also kindly donated by Prof Lovat, one with a light pigmentation and one with a 
dark pigmentation. These pellets were lysed in 300 μl of lysis buffer and then vortexed until 
all cells were disrupted. All lysates were centrifuged at 16,000 g for 5 minutes at 4˚C. All 
lysates were stored at -20˚C, after being flash frozen in liquid nitrogen.  
 
2.4 cDNA  
The following list of pcDNA 3.1 constructs containing a FLAG tag were kindly donated by K. 
Araki and K. Nagata, Kyoto University, Japan: WT PDILT; PDILT C135A; PDILT C420A; PDILT 
C135A/C420A; PDILT DEL498-580; PDILT 520-580; PDILT DEL498-580+C135A/C420A and 
PDILT DEL520-580+C135A/C420A. The Ero1α -myc pcDNA.3.1 construct has been previously 
described (Benham et al 2000) 
 
2.5 Antibodies 
The PDI polyclonal antibody was produced by immunising rabbits with purified rat PDI, as 
described (Benham et al. 2000). In western blotting experiments the PDI polyclonal antisera 
was used at a 1:2000 dilution. The two PDILT antibodies, 2835 and 2836, were produced by 
immunising rabbits with recombinant PDILT, as partly described (Van Lith et al 2005 and 
2007). In western blotting experiments the PDILT antibodies were used at 1:2000, in 
immunofluorescence experiments they were used at 1:200 and in immunohistochemistry 
experiments they were diluted 1:250. The anti-myc antibody, 9B11, was used for the 
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detecting of Ero1α (Cell Signalling Technology, 2279S). In western blotting experiments 9B11 
was used at 1:2000, and in immunofluorescence experiments it was used at 1:200. The anti-
FLAG antibody (Sigma) was used for the detection of the FLAG-tagged PDILT constructs. In 
western blotting experiments it was used at 1:1000. The calmegin and calnexin antibodies 
were produced by and kindly donated by Prof. M Okabe and Prof M. Ikawa (Osaka 
University, Japan). In western blotting experiments these antibodies were used at 1:2000. A 
commercial calmegin antibody was also used (abcam, ab172477). When this antibody was 
used, it has been denoted by the name “CLGN (abcam)”. In western blotting experiments 
ab172477 was used at 1:2000, in immunofluorescence experiments it was used at 1:200 and 
in immunohistochemistry experiments it was used at 1:250. Finally, an actin antibody was 
used to assess equal loading between lysates (abcam, ab8224). It was used at 1:10,000 for 
western blotting.  
 
The secondary antibody donkey anti-rabbit Alexa fluor 594 was used for visualisation in 
immunofluorescence experiments, used at a 1:1000 concentration. Goat anti-Rabbit Alexa 
fluor 568 was also used for visualisation in immunofluorescence and immunohistochemistry 
experiments, used at a 1:1000 and 1:250 respectively. Goat anti-mouse Alexa fluor 488, used 
at 1:1000. The secondary antibodies SARPO (Swine Anti-Rabbit Peroxidase) and GAMPO 
(Goat Anti-Mouse Peroxidase; both from Agilent) were used for western blotting detection 
at 1:3000. 
 
2.6 Bradford Assay 
The protein concentration of all samples was determined with a Bradford assay. The 
Bradford dye (Coomassie Brilliant Blue G-250), when in acidic conditions, converts from its 
cationic form to its anionic form, becoming blue in the process. This anionic form of the 
Bradford dye binds to proteins in the lysate subject to analysis, forming a stable interaction. 
Due to this binding, the concentration of protein in a lysate can be determined by the 
amount of dye present. The amount of dye can be measured by its absorption spectrum at 
595 nm using a spectrophotometer. 
 
Six Bradford standards were produced by the dilution of 1 mg/ml BSA (Sigma) in lysis buffer. 
The standards were 0, 1, 2, 4, 8 and 10 μg/ml. These BSA standard solutions and lysates 
were combined with 10 μl 0.1 M HCl, 80 μl ddH2O and 900 μl Bradford Dye (Biorad). The 
coomassie dye was first diluted 1:5 in ddH20. The absorbances of the BSA standard samples 
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and lysate samples were then measured at 595 nm using a Biophotometer (Eppendorf 
Biophotometer). The Bradford standards were then plotted on a line of best fit. The lysate 
samples were compared to the line of best fit to determine their protein concentration. 
 
2.7 SDS-PAGE 
Samples were prepared for SDS-PAGE by boiling an equal volume of 2 x Laemmli sample 
buffer (65.8 mM Tris-HCl, 26.2 % glycerol, 2.1 % SDS and 0.001 % bromophenol blue, pH 6.8) 
with lysate for 5 min at 95˚C in a heating block. The samples were then centrifuged for 1 min 
at 16,000 g at room temperature. If samples required reduction 50 mM of DTT was also 
included in the sample buffer. Either 10 or 15 well SDS-PAGE gels were cast. Ten well SDS-
PAGE gels were loaded with a maximum volume of 5 μl of lysate and 15 well SDS-PAGE gels 
were loaded with a maximum volume of 10 μl of sample lysate. 
 
The resolving gel was comprised of 4.8 ml ddH20, 2.5 ml 40 % acrylamide, 2.5 ml 1.5 M Tris 
pH 8.8, 100 μl 10 % SDS, 100 μl 10 % APS and 4 μl TEMED. The stacking gel was comprised of 
1.5 ml ddH20, 250 μl 40 % acrylamide, 250 μl 1.0 M Tris pH 8.8, 20 μl 10 % SDS, 15 μl 10 % 
APS and 2 μl TEMED. The resolving gel was pipetted into a gel caster (Hoefer) and left to 
polymerise for 30-45 minutes. Whilst polymerising, the resolving gel was covered with 400-
600 μl of ddH20. Once polymerised, the ddH20 was removed and the stacking gel was 
pipetted into the gel caster, with either a 10 or 15 well gel comb inserted prior to 
polymerisation. The gel was left to polymerise for 5-10 minutes. Following this, the gel(s) 
was loaded and placed into a gel electrophoresis unit (SE250 Mighty Small II Mini Vertical 
Electrophoresis Unit, Hoefer), and then filled with running buffer, produced by diluting 10x 
TGS to 1x TGS in ddH20 (Biorad - 25 mM Tris base, 190 mM glycine and 0.1 % SDS). 5-10 μg 
of the sample protein were loaded alongside a prestained protein ladder (Precision Plus, 
Biorad), to allow identification of protein molecular weights. The sample loaded gel was 
then electrophoresed at 50 mA for 1-2 hours, using a power pack (Biorad PowerPac 300). 
The resultant gel was then analysed by western blotting. 
 
2.8 Western Blotting 
SDS-PAGE gels were produced, as described in Section 2.6, and then subject to protein 
transfer. An Immobilon PVDF membrane (Millipore) was primed by incubating the 
membrane in methanol for 15 seconds. The primed membrane was then stored in transfer 
buffer (25 mM Tris-Base, 190 mM Glycine and 20 % methanol, pH 9-9.4) until use. The gel 
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was then prepared for transfer in a cassette. The cassette was prepared by placing the PVDF 
membrane and gel together, with two filter papers and two sponges either side of this 
arrangement. The sponges and filter papers were soaked in transfer buffer before 
placement in the cassette.  
 
Once the sandwich had been assembled in the cassette, the cassette was closed and 
inserted into the transfer kit (Biorad Mini Trans-Blot Cell), together with an ice-cold cooling 
unit. The transfer kit was then filled with chilled transfer buffer and run at 150 mA for 120-
180 minutes, at room temperature, or run at 30 V overnight, at 4˚C, using  power pack 
(Biorad PowerPac 300). Once transfer was completed, the transfer cassette was 
disassembled and the membrane was extracted. The membrane was then blocked in a 5 % 
w/v milk solution (Tesco Instant Dried Skimmed Milk in TBS-T - 10 mM Tris-Base, 70 mM 
NaCl, 1.75 mM KCl and 0.1 % Tween) overnight, on a rocker at 4˚C. 
 
Following blocking, the membrane was transferred to a 50 ml tube and then washed in TBS-
T a total of five times, incubating the membrane for 5 min between washes. The primary 
antibody was then applied in 1 ml of 2 % milk/TBS-T and the membrane was allowed to 
incubate for one hour. After this incubation, the membrane was then washed five times in 
TBS-T. The secondary antibody SARPO (swine anti-rabbit peroxidase) or GAMPO (goat anti-
mouse peroxidase) was then applied to the membrane in 1 ml of 2 % milk/TBS-T, and 
incubated for 1 hour. After this incubation had elapsed, the membrane was then washed for 
a total of five times in TBS-T.  
 
The membrane was then briefly washed in TBS (10 mM Tris-Base, 140 mM NaCl and 1.75 
mM KCl), with the excess liquid removed by dabbing on paper towel, and then the 
membrane was placed on saran wrap. Next, 500 μl ECL solution (GE Healthcare) was applied 
to the membrane, to allow for band visualisation by chemiluminescence. The excess ECL was 
then dabbed off and the membrane placed on new saran wrap. The membrane was then 
exposed to photographic light sensitive film (ThermoFischer), whilst in a dark room. The film 
was then developed with an X-ray developer machine (XOMAT). 
 
2.9 Transfection 
Transfection was carried out on HT1080 cells, grown to 70-90 % confluency in 6 cm dishes, 




Cells were prepared for transfection by washing the cells with PBS twice. Two different 
transfection solutions were prepared and then applied to the cells. The first solution was 
made with 125 μl of OptiMEM (Gibco, ThermoFischer) and 3.75 or 7.50 μl of Lipofectamine 
3000. The second solution was made with 125 μl of OptiMEM, 5 μl of P3000 Enhancer 
Reagent and either 1 μg or 2 μg of cDNA. Following application of the two transfection 
solutions to the cells, a further 250 μl of OptiMEM was applied to the cells. The cells were 
then incubated in a tissue culture incubator at 37˚C and 5 % CO2. After this hour had 
elapsed, 1 ml of OptiMEM was applied to the cells. The cells were ready for lysis 24-48 hours 
later.  
 
2.10 Immunofluorescence of Adherent Cells  
Cells were grown on 18 mm coverslips in 6 cm dishes, until they were 70-90 % confluent. 
The coverslips were then washed twice in PBS. The coverslips were then prepared for 
immunofluorescence by fixing with 4 % paraformaldehyde, diluted in PBS++ (PBS 
supplemented with 1 mM CaCl2 and 0.5 mM MgCl2, Sigma).  After allowing 15 minutes to fix, 
the cells were washed twice in PBS++. All free aldehyde groups were quenched via 
application of 50 mM NH4CL2 for 15 minutes. Once this time had elapsed, the coverslips 
were washed again three times in PBS++. Cells on the coverslips were then permeabilization 
with 0.1 % Triton-x100, diluted in PBS++. After allowing 10 minutes for the permeabilized to 
be completed, the coverslips were washed again in PBS++. 
Next, 25 μl of primary antibody, at the concentrations described in section 2.5, were applied 
to the coverslips in a 0.2 % BSA solution, diluted with PBS++. The coverslips were left for 20 
minutes and then washed with PBS++ three times.  
 
The relevant secondary antibody was then applied at 1:1000 in 25 μl of 0.2 % BSA solution. 
The secondary antibodies used in this work were the donkey anti-rabbit Alexa Fluor 594, the 
mouse monoclonal Alexa Fluor 568 and the goat anti-mouse Alexa Fluor 488 (all Invitrogen, 
ThermoFischer Scientific). The secondary antibody was incubated with the coverslip for 25 
minutes and following this incubation, the coverslips were washed twice in PBS++. The 
coverslips were incubated with DAPI, diluted to 0.1 ug/ml in PBS++, for 5 minutes.  
 
Following this procedure, the coverslips were briefly washed in ddH2O to remove excess PBS 
and then mounted onto microscope slides using vectashield (Vector laboratories). 
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Immunofluorescence was then imaged using either a Zeiss Apotome or a Zeiss 880 confocal 
microscope.  
 
2.11 Cell Spheroid Immunofluorescence  
Spheroids imbedded in paraffin were produced as described in section 2.2. The paraffin 
blocks were then mounted onto a microtome (Microm HM 330 Microtome) and cut into 4 
μm sections. These sections were mounted onto slides and then baked at 60˚C overnight.  
 
Once adhered to the slides, the spheroid sections were incubated in Histo-Clear (National 
Diagnostics) for 15 minutes. The slides were then hydrated through a series of alcohols. Each 
slide spent 3 minutes in 100 %, 95 % and 70 % ethanol. Finally, the spheroid sections were 
incubated in deionised water for 3 minutes.  
 
The spheroid sections were then subject to antigen retrieval. Sections were heated in a 
microwave at full power in preheated 1x sodium citrate for 10 minutes. 1x sodium citrate 
was produced by diluting a 10x sodium citrate stock (74.4 mM anhydrous sodium citrate) 
1:10 in ddH20. The sections were then allowed to rest for one minute and then they were 
heated again at full power for another 5 minutes in the sodium citrate. Sections were then 
cooled on the bench for 20 minutes and subsequently permeabilized by incubating the slides 
in permeabilizing buffer (0.1 % Triton x100, diluted in 1x PBS) on a rocker for 20 minutes. 
Finally, sections were blocked by incubating the slides in blocking buffer (2 % FBS in PBS with 
0.1 % Tween20) for 30 minutes. 
Primary antibodies, secondary antibodies and the DAPI nuclear stain were then applied to 
the sections in the same manner as described in section 2.10. 
 
2.12 Immunohistochemistry Protocol 
Six human melanoma tissue samples were kindly donated by Prof. Lovat for examination. 
Permission to use this tissue was obtained from the national research ethics committee 
(08/H0906197+5_Lovat). The nature of these tumours is outlined in Table 3. These tumours 
were sectioned, hydrated, subject to antigen retrieval and stained in a similar manner as 






3. Results Section – Chapter 1 
 
3.1. Transfection and localisation of PDILT and Ero1α in transfected HT1080 Cells 
One of the aims of this thesis was to examine how mutations to key structural elements of 
PDILT effect its ability to interact with client proteins. An alignment of the PDI and PDILT 
protein sequences can be seen in Figure 5. The key structural elements of interest are the 
two cysteines present at position 135 and 420 and also the C-terminal extension. In order to 
examine the role of these free cysteines, a series of mutations have already been performed 
and several PDILT constructs have been generated. These were either generated in-house or 
kindly donated to our laboratory by Dr. Araki and Prof. Nagata, Kyoto University, Japan. A 
summary of the PDILT mutants generated for this study can be found in Figure 6. In 
summary, cysteines 135 and 420 in PDILT have been replaced with alanine. The C terminal 
tail domain of PDILT was mutated, with two separate deletions at different points along the 
tail. The final set of constructs combines the cysteine substitution and C-terminal tail 
deletion. These constructs required further evaluation in cell lines. Thus, a series of 
transfection experiments were performed using HT1080 cells to establish their suitability for 
the analysis of these PDILT cDNA constructs and for the comparison of FLAG-tagged and 
myc-tagged PDILT proteins. 
 
HT1080 cells were grown to confluence in 6cm dishes and then transfected with either PDILT 
wt cDNA, Ero1α-myc cDNA, or mock transfected using Lipofectamine 3000 as a transfection 
reagent. Twenty-four hours after transfection the transfected HT1080 cells were lysed using 
MNT lysis buffer. The resulting lysates were then centrifuged at 16000 g to separate the 
nuclear components from the cellular components. Rat testis was also lysed with MNT lysis 
buffer and diluted 1:10 to act as a positive control. These samples were then loaded onto an 
SDS-PAGE gel and run under reducing and non-reducing conditions and blotted with a PDILT 
antibody (2835), a PDI antibody and an anti-Myc antibody (9B11), as the transfected Ero1α 
has a myc tag. The Figure 7A demonstrates that the HT1080 cells were successfully 
transfected with PDILT, as a clear band at ~ 77 kD can be seen. This correlates with a band of 
a similar molecular weight in the positive control, the rat testis lysate. The PDI blot in the 
Figure 7B showed a single band in all lysates at around 55 kD, which would be expected for 
this universally expressed protein. The Figure 7C demonstrates that the transfection of 
Ero1α was also successful, as only the Ero1α transfected lysate had a band present at 
around 60 kD, which is expected given the molecular weight of the protein. These western 
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blot results taken together show that HT1080 cells are suitable hosts for transfection as they 
are able to express transfected proteins at a level that can be detected by western blotting. 



































Figure 5: The Sequence of PDILT compared to PDI. The protein sequence of PDILT compared 





































Figure 6: The Mutant PDILT Constructs. Diagrammatic representation of mutagenesis of the 
PDILT constructs. All constructs also contained a FLAG tag upstream of the KEEL ER retention 
sequence.  
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Figure 7: Western Blot of HT1080 Cell Lysates Transfected with PDILT and Ero1α.  The 
transfected HT1080 cell lysates were run on an SDS-PAGE gel, transferred to PVDF 
membranes and blotted with a PDILT 2835 antibody (A), PDI antibody (B) and an anti-Myc 
antibody (C). An untransfected HT1080 lysate acted as a negative control and a rat testis 
lysate acted as a positive control for PDILT expression. Only the HT1080 + PDILT lysate and 
the rat testis lysate showed bands around the 75 kD, confirming successful transfection. Only 
the HT1080 + Ero1α lysate showed a band around the 55 kD, confirming the transfection of 
Ero1α into HT1080 cells was successful. All lysates showed expression of PDI when blotting 




































To further test the localisation of expression of the transfected proteins, a series of 
immunofluorescence experiments were carried out on HT1080 cells transfected with either 
PDILT or Ero1α. HT1080 cells were grown on cover slips and then either mock transfected or 
transfected with PDILT or Ero1α. The cells were then stained with the primary antibody for 
either PDILT or anti-myc (to identify Ero1α), then the cells were incubated with the 
secondary antibody conjugated to Alexa fluor 594. Cells were also costained with DAPI for 
identification of the nuclei. Figure 8A and Figure 8B show that the HT1080 cells successfully 
transfected with PDILT had perinuclear staining that was consistent with localisation to the 
ER, which would be expected for PDILT. Staining of Ero1α transfected cells was less clear. 
Figure 8C and Figure 8D had some speckled staining throughout the cells but most cells 
demonstrated a stronger intensity of staining around the nucleus, suggesting that Ero1α is 
expressed and is localised to the ER as anticipated. However, the poor transfection efficiency 
observed from the images and the speckled staining seen in the mock transfected images 




























































Figure 8: Immunofluorescence of HT1080 Cells Transfected with PDILT and Ero1α. HT1080 
cells were transfected with PDILT (A-B) or with Ero1α (C-D) or mock transfected (E-F). PDILT 
was detected with a PDILT antibody (2835), panels A and B. Ero1α was detected with an Anti-
myc antibody (9B11), panels C and D. No primary antibody was applied to panel E and F. The 
speckled staining seen in E and F can be used to rule out similar staining in A-D as PDILT or 
Ero1α staining. All cells were co-stained with DAPI. When the HT1080 cells transfected with 
PDILT were stained with the PDILT 2835 antibody, the cells showed perinuclear staining, 
confirming the expected localisation of PDILT. When the HT1080 cells transfected with Ero1α 
were stained with the Ero1α antibody, some cells had perinuclear staining, but punctate 
staining can also be seen in the cells. Images A C E were taken at a ×20 magnification with a 
Zeiss Apotome and images B D F were taken at a ×63 magnification on the same microscope. 
The scale for the 20x magnification images is 50μm and the scale for the x63 magnification 





Given the results from the previous experiments, there was a desire to improve transfection 
efficiency, thus optimisation of transfection experiments were carried out. HT1080 cells 
were grown on coverslips and transfected with Ero1α. Different ratios of cDNA and 
lipofectamine were used to see which conditions improved transfection efficiency. The cDNA 
was either applied to the cells at 1 μg or 2.50 μg together with either 3.75 μl or 7.50 μl 
Lipofectamine. Post transfection, the coverslips were incubated with an anti-Myc antibody  
(9B11) and the secondary antibody coupled to Alexa fluor 594. The coverslips were also 
incubated with DAPI to stain cell nuclei for cell identification. Transfection efficiency was 
measured by counting stained cells within a representative field. Regardless of lipofectamine 
volume, when only 1μg of cDNA was used the transfection efficiency was still poor, as 
transfection efficiency was roughly 2 % when 3.75 μl of Lipofectamine was used (Figure 9A) 
and also roughly 2 % when 7.50 μl of  Lipofectamine was used (Figure 9B). However, when 
the cDNA amount was increased to 2.50 μg there was an observable improvement in 
transfection efficiency. Transfection efficiency improved when this concentration of cDNA 
was combined with 3.75 μl of Lipofectamine, as it increased to roughly 6 % (Figure 9C). 
When 7.50 μl of Lipofectamine was used the transfection efficiency was also increased to 
around 6 % (Figure 9D). While there was a notable difference between 1 μg of cDNA and 2 
μg of cDNA, there was not a dramatic difference between the two Lipofectamine volumes. 
This was still a suboptimal transfection efficiency however and although further optimisation 
could have been performed, it was decided to use 2 μg of cDNA and 3.75 μl of Lipofectamine 
3000 in future experiments.  
 
3.2. Examination of the Impact of Structural Mutations on PDILT Client Interactions 
In order to study how the tail domain of PDILT contributes to its function, PDILT constructs 
with a FLAG tag upstream of the KDEL ER retention sequence were used. The cysteine at 
position 135 was replaced with alanine (PDILT C135A) and the cysteine at position 420 was 
also substituted with alanine (PDILT C420A). Both cysteines were also substituted for alanine 
in a double mutant (PDILT C135A/C420A). The large C terminal extension was deleted at 
positon 498 (PDILT DEL 498-580) and position 520 (PDILT DEL 520-580). The two tail mutants 
were combined with the double cysteine mutant (PDILT DEL 498-580+C135A/C420A and 
PDILT DEL 520-580+C135A/C420A). A wild type FLAG tagged PDILT (PDILT WT) was also used. 
A list of all PDILT constructs used is shown in Figure 6. 
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Figure 9: Initial Optimisation of Transfection of HT1080 cells. Different ratios of Ero1α DNA 
and Lipofectamine 3000 were used to establish transfection efficiency. Ero1α was detected 
using an Anti-myc antibody (9B11), the secondary antibody Alexa Fluor 488 and also 
costained with DAPI. (A) 1 μg cDNA and 3.75 μl lipofectamine (B) 1 μg cDNA and 7.50 μl 
lipofectamine (C) 2.5 μg cDNA and 3.75 μl lipofectamine and(D) 2.5 μg DNA and 7.50 μl 
Lipofectamine, In each case, a relatively low transfection efficiency was observed, but 
transfected cells (green) demonstrated perinuclear ER staining as expected. The scale for the 





























The effects on PDILT of substituting position 135 and 240 cysteines for alanine has previously 
been examined by van Lith et al. 2004. Those experiments were carried out on constructs 
expressing myc tagged PDILT, unlike these constructs, which express FLAG tagged PDILT. 
Thus, one of the aims of this thesis was to compare the expression and behaviour of the 
FLAG-tagged PDILT with the myc-tagged PDILT proteins.  
In order to examine what effect these mutations had, the expression of PDILT and PDILTs 
ability to interact with clients was assessed through a series of western blotting 
experiments. HT1080 cells were grown to confluency in 6 cm dishes and then transfected 
with the PDILT constructs. The transfected HT1080 cells were then lysed and run on an SDS-
PAGE gel under reducing and non-reducing conditions and blotted with a PDILT antibody 
(2835). The transfected HT1080 lysates were compared against a mock transfected HT1080 
cell lysate as a negative control and a rat testis lysate as a positive control. Figure 10 
demonstrates the effects of each mutation on the ability of PDILT to bind with client 
proteins. The HT1080 lysate transfected with the wild type PDILT demonstrated the 
expected result, Figure 10 Lane 1, with a high weight molecular series of bands forming at 
250 kD, which is consistent with published PDILT complex formation with disulfide-bonded 
client proteins (van Lith et al. 2007). PDILT C135A showed some loss of the high molecular 
weight banding pattern under non-reducing conditions (Figure 10 Lane 2) with some 
complexes visible at a slightly lower molecular weight. This suggests that PDILT C135A is able 
to form some interactions with client proteins, but not the full range as the wild type PDILT. 
A similar observation was seen with PDILT C420A, Figure 10 Lane 3, with a different high 
molecular weight band being observed at a lower molecular weight than PDILT WT, again 
demonstrating that the loss of a single cysteine facilitates some client interactions. When 
both cysteine mutations were combined, the PDILT C135A/C420A protein completely lost 
high molecular weight band formation, Figure 10 Lane 4, suggesting that both cysteines 
were essential for the ability to interact with client proteins in a disulfide-dependent 
manner. These results were consistent with those observed for PDILT-myc tagged mutants 
(van Lith et al 2010), demonstrating that differences in the pre-KDEL tag do not influence the 
binding profile of PDILT.   
                                                                                                                                                                                   
Removal of the C terminal extension of PDILT (whilst retaining the KDEL) had a different 
effect on protein-protein interactions. The C terminal deletion at position 489, PDILT DEL 
498-580, caused an increase in complex formation over the 150 kD range, Figure 10 Lane 5, 
with a similar effect seen when the C terminal section was deleted at position 520 (PDILT 
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DEL 520-580), Figure 10 Lane 6. This banding pattern suggests that PDILT is interacting either 
with a greater number of client proteins or with higher affinity to the same client proteins 
when the C terminal extension is removed. When the tail and cysteine mutations were 
combined, there was a complete absence of any high molecular weight bands (for both 
PDILT DEL 498-580+C135A/C420A and PDILT DEL 520-580+C135A/C420A), suggesting a 
complete loss of client interactions, Figure 10 Lane 7 and 8. This result suggests that the 
C135 and C420 residues are the primary determinants of disulfide-dependent client 
interaction, but that the tail domain can control the magnitude of client access.  
                                                                                                                                                                  
Observation of the reducing gel of these samples (Figure 10B) demonstrated that the 
interactions observed under non-reducing conditions were disulfide dependent, as the 
higher molecular weight complexes were dispersed upon reduction with DTT. The monomer 
band for PDILT+PDILT DEL 498-580+CI35A/C420A ran at a slightly higher molecular weight 
than expected, but the other monomers of the different PDILT mutants could be detected at 
the expected molecular weight in the reducing gel. The control actin blot (Figure 10C) shows 
a reasonable level of protein loading. 
In order to confirm that the proteins detected were not cross-reacting with the PDILT 
antisera, a repeat of the western blot experiment was performed on the same lysates, 
blotting back with an anti-FLAG antibody, Figure 11A and B. The same overall pattern of 
PDILT monomer migration and disulfide-dependent client binding was seen as when the 
PDILT 2835 antibody was used. As a control, the lysates were probed for the expression of 




































Figure 10: Western blot of HT1080 lysates transfected with PDILT mutants using a PDILT 
Antibody. The different PDILT constructs listed in Table 1 were transfected into HT1080 cells 
and lysates were run on SDS-PAGE under non-reducing conditions (NR) (A) and reducing 
conditions (R) (B) and blotted with the PDILT 2835 antibody. Actin was used as a loading 
control (C). Under non-reducing conditions, WT PDILT formed a high molecular weight band 
at 250 kD, confirming PDILT complex formation (Lane 1). PDILT C135A and C420A lost some 
client interactions (Lanes 2 and 3). PDILT C135A+C420A completely lost high molecular 
weight bands, suggesting this mutant was unable to interact with disulphide-dependent 
client proteins (Lane 4). Both PDILT DEL 498-580 and PDILT DEL 520-580 increased the 
number of client protein interactions (Lane 5 and 6). When both mutations were combined 
in PDILT DEL 498-580+C135A/C420A and PDILT DEL 520-580+C135A/C420A, there was 
complete abolishment of high molecular weight bands (Lane 7 and 8). PDILT monomers were 
confirmed under reducing conditions. The actin antibody confirmed a reasonable level of 




Figure 11: Western blot of HT1080 lysates transfected with PDILT mutants using an Anti-
FLAG Antibody. The different PDILT constructs listed in Table 1 were transfected into HT1080 
cells and then analysed on an SDS-PAGE by western blotting under non-reducing (NR) 
conditions (A) and reducing (R) conditions (B) and blotted with an Anti-FLAG antibody. In the 
non-reducing blot, WT PDILT formed a range of high molecular weight bands, as seen in 
Figure 4 (Lane 1). PDILT C135A and C420A both showed a similar loss of client interactions 
(Lanes 2 and 3) and PDILT C135A+C420A had a total loss of any high molecular weight bands 
(Lane 4). Both PDILT DEL 498-580 and PDILT DEL 520-580 also showed similar banding to 
Figure 4, as both had an increase in the number of client protein interactions (Lane 5 and 6). 
PDILT DEL 498-580+C135A/C420A and PDILT DEL 520-580+C135A/C420A both had a 
complete loss of high molecular weight bands, again, comparable to Figure 4 (Lane 7 and 8). 
In the reducing blot, the monomer bands for PDILT WT mutant and the PDILT DEL 498-580 




























Having established that the PDILT cysteine and tail mutants had different client binding 
profiles, an experiment was performed to investigate the subcellular localisation of each of 
the PDILT mutant proteins. HT1080 cells were grown on coverslips, fixed, permeabilized and 
subjected to immunofluorescence. Each of the coverslips were incubated with the primary 
antibody PDILT 2835 and the secondary antibody labelled with Alexa fluor 594. Cells were 
also counterstained with DAPI to allow cell identification. All the transfected HT1080 cells 
showed strong perinuclear staining consistent with ER localisation, which indicates that all 
the PDILT variants were successfully targeted to the ER, Figure 12 and 13. The HT1080 cells 
transfected with PDILT DEL 520-850+C135A/C420A showed some punctate staining, 
suggesting that some of the PDILT mutant proteins may reside in ER derived vesicles, or are 
being trafficked for degradation via the lysosomal pathway. This would be consistent with 
some of the western blotting data in Figure 11, showing that the monomer bands for PDILT 
WT and PDILT DEL 498-580 were of lower staining intensity in the reducing western blot. 
However, other explanations could also explain the absence of the monomer bands and the 
immunofluorescence experiments would need to be repeated, for example using an 
independent cell line for transfection and with co-labelling of both ER and endosomal-
lysosomal markers. Further experimental analysis will be required to understand whether 
overexpression of PDILT leads to punctate formation, whether a subset of mutant PDILT 
proteins is prone to misfolding, or whether PDILT is able to access post-ER compartments 














Figure 12: Immunofluorescence of HT1080 Cells Transfected with PDILT mutants. The initial 
four PDILT constructs listed in Table 1 were transfected into HT1080 cells and the cell 
prepared for immunofluorescence. The transfected cells were fixed with formaldehyde and 
then permeabilized with 0.1 % Triton x100. The PDILT mutants were then visualised with a 
PDILT antibody (2835) and the secondary antibody Alexa Fluor 594. All cells were costained 
with DAPI. Cells were imaged at ×20 magnification and at ×63 magnification with a Zeiss 
Apotome. All PDILT mutant proteins localised to a perinuclear region, consistent with the ER. 
White arrows indicate positive expression. The scale for the 20x magnification images is 

























































Figure 13: Immunofluorescence of HT1080 Cells Transfected with PDILT mutants. The last 
four PDILT constructs listed in Table 1 were transfected into HT1080 cells and the cell 
prepared for immunofluorescence. The transfected cells were fixed with formaldehyde and 
then permeabilized with 0.1 % Triton x100. The PDILT mutants were then visualised with a 
PDILT antibody (2835) and the secondary antibody Alexa Fluor 594. All cells were costained 
with DAPI. Cells were imaged at ×20 magnification and at ×63 magnification with a Zeiss 
Apotome. All PDILT mutant proteins localised to a perinuclear region, consistent with the ER. 
White arrows indicate positive expression. The scale for the 20x magnification images is 
50μm and the scale for the x63 magnification images is 20μm.  
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4. Results Section – Chapter 2 
 
4.1. Analysis of Melanoma Cell Lines for Testis Specific ER Protein Expression 
To examine the possibility that PDILT might be expressed in melanoma, we decided to test a 
variety of melanoma cell lines for PDILT expression and other testis specific ER proteins. The 
six melanoma cell lines were A375, WM35, C8161, WM1361, WM164 and SKMEL28 (kindly 
provided by Prof Penny Lovat (Dermatological Sciences at Newcastle University). These cell 
lines were chosen due to their different mutational states in BRAF and NRAS. The mutations 
present in each of the cell lines are summarised in Table 2.  
 
Initially, the A375, WM35 and the C8161 cell lines were grown in 6 cm cell dishes and lysed 
with MNT lysis buffer. The resultant lysates were run on an SDS-PAGE gel, transferred to 
PVDF membranes and blotted with a PDILT antibody (2835) and an actin antibody (Figure 
14). Interestingly, the C8161 cell lysate returned a positive result, with a band forming 
around the 77 kD mark, which is consistent with the correct molecular weight of PDILT and 
also matches the weight of the band produced by the rat testis control. This suggests that 
PDILT was expressed in the C8161 cell line but given that this was shown with a single PDILT 
antibody, another series of experiments were undertaken. All six melanoma cell lines were 
analysed for PDILT expression with two antibodies and for expression of other testis specific 
ER proteins. 
 
To test if the observed PDILT expression in C8161 cells was reproducible, each of the cell 
lines were grown in 6 cm cell dishes and lysed with MNT lysis buffer. The resultant lysates 
were run on an SDS-PAGE gel and transferred to PVDF membranes which were blotted with 
two different PDILT antibodies (2835 and 2836), a CLGN antibody, a CNX antibody and an 
actin antibody. Calmegin was analysed because it is a testis specific ER protein and it is 
known that testis-specific proteins can be derepressed in melanoma (so-called testis-tumor 
antigens) (Caballero and Chen 2011). Calnexin was analysed as a positive control because it 
is a ubiquitously expressed ER protein. All the melanoma cell lysates were compared against 
a rat testis lysate, which acted as a positive control for testis-specific protein expression. 
Figure 15A and Figure 15B showed that none of the melanoma cell lysates were positive for 
PDILT, including C8161. Neither the PDILT 2835 nor the PDILT 2836 antibody revealed a band 
around the 75 kD mark, which is the molecular weight of PDILT. This conflicts with the 
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positive result shown in Figure 14. This could be explained by the difference in passage 
number between the cells lysed. PDILT was evident in the C8161 cell line when cells were 
lysed at a low passage, at passage 10 (Figure 14), but the C8161 cells appeared to lack 
expression at a higher passage number, at passage 27 (Figure 15). Figure 15C demonstrates 
that CLGN was expressed in the C8161 lysate, with the molecular weight of the resultant 
band, around 100 kD, matching that of the band in the positive control. This suggested that 
calmegin is expressed in the C8161 cell line. Calnexin was expressed in all of the melanoma 
cell lines, Figure 15D, as shown by a band around the 80 kD mark, which corresponds with a 
similar-sized band in the positive control. This was expected given the ubiquitous expression 
of CNX in all cells. Both the rat testis lysate and the WM35 lysates had doublet CNX bands, 
one at ~ 90 kD and the other at ~ 80 kD, which was unexpected. This doublet may represent 
two distinct populations of CNX, which have different post translational modifications. The 























































Table 2: Melanoma Cell Line 
The BRAF and NRAS mutation status of the cell lines is provided below. 
Cell Line BRAF NRAS 
A375 V600E wt 
WM35 V599I wt 
C8161 wt wt 
WM1361 wt Q61R 
WM164 V600E wt 
SKMEL28 V600E wt 
CHL1 wt wt 
Figure 14: Western Blot of Melanoma Cell Lysates using a PDILT Antibody. Melanoma cells 
were lysed with MNT lysis buffer, run on an SDS-PAGE gel, transferred to PVDF and the 
membrane blotted with a PDILT antibody (2835) (Panel A) and an actin antibody (Panel B). 
An HT1080 lysate acted as a negative control and a rat testis lysate acted as a positive 
control for PDILT. The PDILT antibody (2835) revealed a positive band around the 75 kD 
mark, which migrated at the same position as the positive control, suggesting C8161 cells 




































Figure 15: Western Blot of Melanoma Cell Lysates testing for a Variety of ER Proteins.  
Melanoma cells were lysed with MNT lysis buffer, run on an SDS-PAGE gel, transferred to 
PVDF and the membrane blotted with two PDILT antibodies (2835 and 2836) (A and B), a 
CLGN antibody (C), a CNX antibody (D) and an actin antibody (E). A rat testis lysate acted as 
a positive control. When blotting with the PDILT 2835 antibody and the PDILT 2836 
antibody, none of the melanoma cell lysates returned a positive result, suggesting that 
none of the melanoma cells expressed PDILT. When blotting back with the CLGN antibody, 
a single band formed in the C8161 cell lysate lane around 80 kD (Lane 3), which 
corresponded to the band in the positive control. This suggests that C8161 expresses CLGN. 
All of the lysates expressed CNX when blotted with the CNX antibody. However, both the 
WM35 cell lysate and the rat testis cell lysate had a CNX doublet. The actin blot back 






4.2 Confirming Calmegin Expression in the C8161 Melanoma Cell Line  
Following on from the observation that the C8161 cell line did express the testis specific ER 
protein calmegin, further testing was conducted to confirm the expression of calmegin and 
to explore the characteristics of its expression. 
 
To confirm the expression of calmegin in the C8161 cell line, a C8161 cell lysate was 
compared against a WM164 cell lysate (a negative control due to its observed lack of 
calmegin expression) and against a rat testis lysate, which acts as a positive control. The 
lysates were run on an SDS-PAGE gel and blotted with two CLGN antibodies, one was a gift 
from M. Okabe, Osaka, and the other was commercially available (abcam, ab172477) from 
abcam. The CLGN antibody (abcam, ab172477) was used to confirm the initial identification 
of calmegin. As shown in Figure 16, both CLGN antibodies detected a band at ~100 kD in the 
C8161 lysate, in agreement with the positive control. However, the Okabe laboratory CLGN 
antibody gave a signal that had a slight reduction in molecular weight when compared to the 
positive control. The actin blot shows that there was mostly equivalent loading of sample 
between the lanes. 
 
To further test CLGN and PDILT expression and to examine cellular localisation of CLGN, an 
immunofluorescence experiment was carried out (Figure 17). Both C8161 and WM164 cells 
were grown on cover slips, fixed, permeabilized and then incubated with either a PDILT 
2835, CLGN or CNX antibody, followed by the donkey anti-rabbit secondary Alexa 594. The 
cells were also co-stained with DAPI to allow for nuclear identification. The results were 
consistent with what was observed in Figure 15. When both cell lines were incubated with 
the PDILT 2835 antibody, neither of the cell lines showed any cellular staining for PDILT. 
However, when both cell lines were incubated with the CLGN antibody, only the C8161 cell 
line demonstrated staining. This adds further evidence that C8161 expresses CLGN and also 
that it localises to the ER, as the staining in the cell was perinuclear in nature. The WM164 
cell line had no CLGN staining and this observation was consistent with the previous western 
blotting result seen in Figure 15. When the cells were incubated with the CNX antibody, both 




From this series of experiments it was clear that the C8161 cell line expressed calmegin and 
it localised to the ER, given the results from the western blotting and immunofluorescence 
experiments. The expression of PDILT in the melanoma cell lines is less clear. Given the 
difference in passage number from the positive result (Figure 14) and negative result (Figure 
15), it is possible that PDILT is only expressed in the C8161 cell line when at a low passage. 
This should be examined in the future with C8161 lysates originating from different passage 
































































Figure 16: Western Blot Confirming Calmegin Expression in C8161 Cells. The C8161 lysate 
and the WM164 cell lysate produced for Figure 15 were rerun on an SDS-PAGE gel and 
western blotted with two independent CLGN antibodies (A and B). A rat testis lysate was 
used as a positive control. In (A), the C8161 cell lysate was positive for CLGN but the protein 
appeared to run at a lower molecular weight in comparison to the positive testis control. In 
(B) C8161 was also positive for CLGN, but the molecular weight more closely matched the 
positive control. The lack of reactivity in CNX-positive WM164 cells demonstrates that the 
CLGN antibody does not cross-react with CNX. The actin antibody (C) demonstrated 






































Figure 17: Immunofluorescence of C8161 and WM164 Cells. C8161 and WM164 cells were 
grown on 18 mm coverslips, fixed, permeabilized and then incubated with a PDILT antibody 
(2836) (A B G H), a CLGN antibody (C D I J) and a CNX antibody (E F K L). These cells were 
then imaged at ×63 magnification and at ×100 magnification with a Zeiss Apotome. Neither 
the C8161 nor the WM164 cells showed any staining for PDILT. Only the C8161 cells showed 
perinuclear staining for CLGN, consistent with ER localisation. The WM164 cells showed no 
CLGN staining, consistent with previous experiments. Both the C8161 and WM164 had 
perinuclear staining for CNX, as expected for a ubiquitously expressed ER protein. White 




4.3. Characterising Calmegin Expression in Mutant BRAF Melanoma Cell lines  
 
Interestingly, C8161 was the only cell line analysed with a wild type form of BRAF 
(Information provided by Prof P. Lovat). Cell lines A375, WM164 and SKMEL have the 
melanoma mutation of V600E BRAF and WM35 cell line has a V599I mutation in BRAF. This 
genetic difference could explain why only the C8161 cell line expresses CLGN. This difference 
could allow for the potential targeting of CLGN for wild-type BRAF melanoma drug 
treatment, given that wt BRAF melanomas are resistant to current drug therapies. To 
examine whether other wt BRAF cell lines also demonstrate CLGN expression another wild 
type BRAF cell line, CHL1, was obtained for further testing. The cells were grown in 6 cm 
dishes alongside the C1816 and WM164 cells and lysed with MNT lysis buffer. The lysates 
were run on an SDS-PAGE gel alongside two melanocyte lysates with different pigmentation 
levels, light and dark. The melanocytes were analysed to test if normal melanocyte cells 
express CLGN. A rat testis lysate was used as a positive control. The proteins from the gel 
were transferred to a PVDF membrane which was probed with a CLGN antibody and an actin 
antibody (Figure 18). Both the C8161 and the CHL1 lanes had positive bands around 80 kD, 
corresponding to the positive band in the rat testis positive control lane. This lends more 
evidence to the hypothesis that the expression of CLGN correlates with melanoma cells that 
maintain a wild type form of BRAF. The WM164 lysate was negative for CLGN expression, 
which concurred with the previous results. Both the light and dark pigmented melanocyte 
lysates were negative for CLGN expression. This suggests that the expression of CLGN 
observed in both the C8161 and CHL1 cell line occurs post cancer initiation. The actin blot 
















































Figure 18: Examining CLGN Expression in WT BRAF Melanoma Cell Lysates and Melanocyte 
Lysates. Melanoma cells and melanocyte cell pellets were lysed with MNT lysis buffer and 
run on a SDS-PAGE gel. The proteins were transferred to a PVDF membrane and 
immunoblotted with (A) a CLGN antibody (abcam, ab172477) and (B) an actin antibody. A rat 
testis lysate acted as a positive control. Both of the C8161 and CHL1 lysates were positive for 
CLGN expression whereas the melanocytes did not express CLGN. The actin blot shows that 
the CHL1 cell expression of CLGN is likely to be underestimated given the unequal loading 




Previous research on the relationship between ER stress and cancer has shown that the 
expression of certain ER proteins, such as GRP 78/BiP and GRP94 in colon cancer, acts to 
reduce ER stress and thus avoid self-induced apoptosis of the cell. It has also been shown 
that general ER stress, such as environmental stress, acts to upregulate these proteins 
(Welch 1992). In order to explore this, C8161 cells and WM164 cells were grown in spheroid 
culture and incubated for 4, 6 or 8 days. This was done to induce a hypoxic core at the 
centre of the spheroid. The resultant spheroids were then lysed and run on an SDS-PAGE gel 
for western blotting or fixed in paraffin and then subject to immunofluorescence following 
antigen retrieval. The western blotting data is shown in Figure 19. Lysates were produced by 
lysing 10 spheroids per sample in MNT lysis buffer, harvested at each of the different time 
points. For the western blotting experiments, these lysates were compared against a 
monolayer lysate from each of the cell lines. A rat testis lysate was also used as a positive 
control. Each set of samples was blotted with a CLGN antibody (abcam, ab172477), a PDILT 
antibody (2835) and the actin antibody. 
 
Figure 19A shows that only the C8161 cell line was positive for CLGN and that regardless of 
the time point of harvesting, there was a consistent equal expression of CLGN. This suggests 
that neither the increased environmental stress from hypoxic conditions nor the spheroid 
morphology of the cells impacted on the expression of CLGN. The WM164 spheroids showed 
no expression of CLGN at any time point, suggesting that neither spheroid morphology nor 
hypoxic conditions induced CLGN expression.  
 
Figure 19B shows the expression data for PDILT using the PDILT 2835 antibody. Neither the 
C8161 nor the WM164 cell line, regardless of time point of spheroid harvesting, had any 
detectable expression of PDILT. This concurs with previous results and it also suggests that 
neither spheroid morphology nor hypoxic conditions induces PDILT expression in either cell 
line, at least at later passage numbers. Figure 19C shows the expression of actin and 











































Figure 19: Western Blot of C8161 and WM164 Melanoma Spheroids. The C8161 and 
WM164 cell lines were used to produce spheroids which were harvested at days four, six 
and eight. Ten of these spheroids were isolated and lysed with an MNT lysis buffer and run 
on an SDS-PAGE gel. Lysates from monolayers of each of the cell lines were also ran to 
control for the spheroid morphology. A rat testis lysate acted as a positive control.  The 
resultant western blot was probed with a CLGN antibody (abcam, ab172477) (A), a PDILT 
antibody (2835) (B) and an actin antibody (C). When blotting with the CLGN antibody, all 
the C8161 lysates showed expression of CLGN, having a band form around the 100 kD mark 
that matched the positive control. However, there was no difference in level of CLGN 
expression between any of the spheroids or the monolayer lysate. None of the WM164 
lysates demonstrated CLGN expression, consistent with previous results. When blotting 
back with the PDILT antibody, none of the lysates showed PDILT expression. The data 
shows that neither spheroid morphology nor hypoxic conditions can induce PDILT or CLGN 
expression in either melanoma cell line. The actin blot shows equivalent levels of protein 




Spheroids were also harvested for immunofluorescence. Spheroids were imbedded into 
agar, and then imbedded into paraffin. The resultant paraffin blocks were sectioned and 
then subject to antigen retrieval with 74.4 mM sodium citrate. Post antigen retrieval, each of 
the sections were incubated with either no primary antibody, a PDILT antibody or a CLGN 
antibody. They were also incubated with the donkey anti-Rabbit secondary Alexa 568 and 
DAPI to stain cell nuclei. The results are shown in Figure 20. The C8161 spheroids, regardless 
of the time point of harvesting appeared to express a similar level of calmegin, as judged by 
staining around the periphery of the spheroid. One possibility is that the expression of CLGN 
only occurred at the external of the cell due to loss of CLGN expression at the hypoxic core 
of the spheroid. However, there was also some peripheral staining of PDILT. Given the lack 
of PDILT staining from the western blotting data for both cell line spheroids and the lack of a 
positive control (i.e. a spheroid of HT0180 cells transfected PDILT), the peripheral staining 
obtained in these experiments is unlikely to be genuine.  
 
The WM164 spheroids (Figure 21) showed no detectable CLGN expression at any time point, 
as there was no staining in any part of the spheroid. Similar to the C8161 spheroids, the 
results seem to suggest that PDILT is expressed in the WM164 spheroids as there was similar 
staining at the periphery of the spheroid. For the WM164 spheroids, the spheroids 
incubated with no primary antibody produced poor quality images. This made ascertaining 
the expression of different proteins difficult. Further experiments with additional controls 
would be required to definitively confirm whether or not PDILT is expressed in spheroids 















Figure 20: Immunofluorescence of C8161 Melanoma Spheroids. Embedded spheroids of the 
C8161 cells were sectioned, subject to antigen retrieval and incubated with either no primary 
(A-C), a CLGN antibody (abcam, ab172477) (D-F) or a PDILT 2835 antibody (G-I). The sections 
were then imaged at ×20 magnification with a Zeiss 880 microscope. The C8161 spheroids 
incubated with the PDILT antibody showed some peripheral staining, suggesting that the 
spheroid expressed PDILT at the periphery. When incubated with CLGN, the same peripheral 





































Figure 21: Immunofluorescence of WM164 Melanoma Spheroids. Embedded spheroids of 
the WM164 cells were sectioned, subject to antigen retrieval and incubated with a CLGN 
antibody (abcam, ab172477) (A-C) or a PDILT 2835 antibody (D-E). The sections were then 
imaged at ×20 magnification with a Zeiss 880 microscope. The WM164 spheroids showed no 
expression for CLGN. However, the WM164 spheroids showed similar peripheral staining for 
PDILT that was seen in the C8161 spheroids, suggesting that the spheroid expressed PDILT at 
the periphery. White arrows indicate positive expression. The scale for the 20x magnification 





































4.4. CLGN and PDILT Expression in Human Melanoma Tumours 
 
To examine if the expression of CLGN that was observed in wild type BRAF melanoma cell 
lines also occurs in human melanoma tumours, several human tumours of different BRAF 
mutational states were examined by immunohistochemistry. The mutational status of these 
tumours is listed in Table 3. These tumours were already imbedded in paraffin and were 
thus sectioned and mounted on slides, subject to antigen retrieval with sodium citrate and 
incubated with the two PDILT antibodies (PDILT 2835 and 2836) and the commercial CLGN 
antibody. The tumours were also costained with DAPI to allow for nuclear identification 
(Figure 22). Each of the tumours, regardless of the antibody used, had a pattern of dispersed 
staining that was not cell specific. This was likely caused by either using too high a 
concentration of primary or secondary antibody, or arose from incomplete blocking. Due to 
the lack of specificity in the antibody signal, it was not possible to determine whether CLGN 
or PDILT was expressed in any of these tumours. This series of experiments should be 
repeated following an optimisation of the antibodies and antigen retrieval method.  
However, taken together, the data presented in this results chapter suggests that CLGN is 
likely to be expression in some human melanoma and it remains possible that PDILT is also 

































Table 3: Human Melanoma Tumours 
List of all tumours used in experiments. Each tumour has information regarding the sex of the 
patient, the age of the patient when the tumour was extracted, the stage of the tumour and its 
mutational states regarding BRAF and NRAS. 






ACC Tumour Stage 
at Diagnosis  
BRAF NRAS 
M018 Melanoma F 42 IIA wt wt 
M040 Melanoma F 58 IIA wt wt 
M044 Melanoma F 48 IB V600E wt 
M045 Melanoma M 26 IIC V600E wt 
M046 Melanoma M 35 II V600E wt 
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Figure 22: Immunofluorescence of Human Melanoma Tumours. The paraffin imbedded 
tumours were sectioned, subject to antigen retrieval and incubated with both the 2835 and 

























5.1 Expression of PDILT in HT1080 cells 
This thesis began with examining the expression of transfected constructs in HT1080 cells. 
The ability of HT1080 cells to express PDILT was confirmed firstly by western blotting 
(Chapter 3.1 – Figure 7) and by immunofluorescence (Chapter 3.1 – Figure 8). However, it 
was noted that the transfection efficiency in the initial immunofluorescence experiments 
was relatively poor, being only around 5 %. Transfection efficiency is influenced by a number 
of different factors, with one of the most prominent factors being the ratio of nucleic acid to 
transfection reagent (Kim and Eberwine 2010). To investigate if this impacted on the success 
of the transfection, different volumes of vector and transfection reagent were used (chapter 
3.2 – Figure 9). It was found that using 2.50 ug of cDNA and a lipofectamine volume of either 
3.75 μl or 7.5 μl gave the highest transfection efficiency. These experiments demonstrated 
that HT1080 cells are suitable cells for the expression of PDILT and transfection of PDILT 
constructs. However, the relatively poor transfection efficiency suggests that generating 
stable transfected cell lines for the study of PDILT mutants should be addressed in the 
future. An alternative solution is to develop an immortalised cell line from testis that can 
stably express PDILT, as this would eliminate the issues surrounding transfection, such as the 
need to validate successful transfection and the variable transfection efficiency. However, 
attempts to establish stable post-meiotic germ cells in culture have not been possible by any 
laboratory up to now (Staub 2001).  
5.2 Mutations to Key Structural Elements of PDILT Impact on its Ability to Interact 
with Client Proteins 
In this thesis, an analysis was carried out on proteins lacking the C-terminal domain and 
proteins lacking two key cysteines present in PDILTs structure. How these elements 
contribute to the ability of PDILT to bind to client proteins in the ER was investigated. van 
Lith et al. 2004 described several differences between PDILT and the classical PDI protein 
structure. Two of these identified differences between PDILT and PDI are the two cysteines 
present in PDILT, at position 135 and 420, one of which is away from the oxido-reductase 
active site. These cysteines were targeted for study by substitution (to alanine) because they 
are solvent exposed and previously suggested to play a role in binding to client proteins (van 
Lith et al. 2007). The other major difference between PDILT and the PDI is the large C-
terminal extension, which increases the size of the protein to 67 kDa. Thus deletions at two 
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different positions (498 and 520) were studied. The “tail” mutants were also combined with 
the cysteine mutants. The cDNAs used in this study, including constructs kindly provided by 
the Nagata laboratory, are summarised in chapter 3.1 – Figure 6. It has previously been 
shown by van Lith and Benham that myc-tagged PDILTC135A and Myc-tagged PDILTC420A 
displayed altered disulphide-dependent binding to putative client and co-chaperone 
proteins (van Lith et al. 2007). In this thesis, the behaviour of FLAG tagged PDILTC135A and 
Flag tagged PDILTC420A was investigated to address whether the nature of the tag 
influenced the interactions, and to validate alternative PDILT cDNA reagents. The FLAG 
tagged mutant proteins were analysed by western blotting, to observe how each of the 
individual mutations effected PDILTs ability to form disulphide dependent interactions with 
client proteins (Chapter 3.2 – Figure 10 and 11).  
The WT FLAG tagged PDILT protein formed high molecular weight complexes around 250 
kDa under non-reducing SDS-PAGE and showed the presence of a high number of 
PDILT/client complexes, as expected from the literature (van Lith et al. 2007). The single 
cysteine substituted mutants, C135A and C420A, both saw a reduction in size of the high 
molecular weight bands, consistent with results obtained with the equivalent myc-tagged 
constructs.  Whilst there was a loss of some client interactions, there was not a total 
abolishment of all interactions. This concurs with the results presented in van Lith et al. 
2007. However when both cysteines are substituted out, in the C135A/C420A mutants, 
there was a total abolishment of all disulphide dependent client interactions. This 
demonstrated that all detectable client interactions through disulphide bonds are mediated 
by the solvent-exposed cysteines present at position 135 and 420. The two tail deleted PDILT 
mutants, PDILT DEL 498-580 and PDILT DEL 520-580, caused the formation of more bands 
over a large kDa range, suggesting that there was an increase in the number or extent of 
client interactions. From this finding, it is plausible to suggest that the tail of PDILT may 
regulate the interaction between PDILT and client proteins, as there was a large increase in 
the number of interactions once it was removed. However, it is also possible that the tail-
deleted PDILT constructs misfold to some extent and are targeted to alternative disulphide-
dependent interactions involved in ER protein folding and degradation.  
When the cysteine mutations were combined with the tail deletions DEL 498-
580+C135A/C420A and DEL 520-580+C135A/C420A, there was a complete absence of a high 
molecular weight band, suggesting that all disulphide dependent client interactions were 
abolished. This is to be expected and demonstrates that the tail does not mediate disulphide 
dependent interactions away from the two solvent exposed cysteines. The monomer form of 
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PDILT was seen in the majority of the mutants, but monomer bands were absent for the 
PDILT WT and PDILT DEL498-580 mutants. This lack of detection could be explained by 
possible degradation of the translated mutants. This is possible because both of these 
mutants contain the FLAG tag and the PDILT DEL498-580 mutant had part of its C-terminal 
deleted. These structural alterations could impact on the folding of these mutants to such an 
extent that they become targeted for degradation by the ER surveillance machinery. 
However, the lack of bands could be explained by experimental issues, such as an air bubble 
forming (during transfer) over the same area as the expected weight area of PDILT 
monomers of these mutants. 
The cellular localisation of PDILT was also explored with a series of immunofluorescence 
experiments in HT1080 cells (chapter 3.2 – Figure 12 and 13). Regardless of the PDILT 
construct, there was a strong level of perinuclear staining for successfully transfected cells. 
From this result, it can be concluded that the FLAG tag does not interfere with ER 
localisation of PDILT, tail and that C135A, C420A and the tail are not required for localising 
PDILT to the ER of the cell. However, co-staining with a range of ER protein markers, and the 
use of higher resolution microscopy, will be required to determine whether there are any 
differences in localisation to putative ER domains. Interestingly, there was also some 
punctate staining throughout some of the transfected cells, with the clearest example of this 
seen in the cells expressing PDILT DEL 520-580+C135A/C420A shown in Chapter 3.2 - Figure 
13. This observation could explain some of the loss of the monomer forms seen in the 
accompanying western blots, if the mutated proteins were identified as misfolded proteins 
and trafficked for degradation along the autophagic/lysosomal pathway. Further co-
localisation experiments with lysosomal/ERAD/autophagic markers would be required to 
investigate this possibility. 
5.3 Calmegin is Expressed in WT BRAF Melanoma Cell Lines 
This thesis also investigated the possibility that PDILT was expressed in melanoma cells, 
following on from the observation that a selection of tumours in the Human Protein Atlas, 
sourced from both males and females between the ages of 50-80, stained positive with an 
antibody raised against PDILT. Six melanoma cell lines were donated by Prof Lovat and these 
cell lines were grown to confluency, lysed with an MNT lysis buffer and analysed by SDS-




Initially, only three of the cell lines were tested for PDILT expression using a PDILT antibody 
(2835). Of the three cell lines tested, only the C8161 cell lysate demonstrated expression of 
PDILT (Chapter 4.1 – Figure 14). In order to confirm this expression, all six melanoma cell 
lines were analysed. The resultant gels were blotted using two distinct PDILT antibodies and 
a variety of other ER protein antibodies. Immunoblotting with the two PDILT antibodies, 
2835 and 2836, revealed that none of the cells expressed PDILT (Chapter 4.1 - Figure 15). 
The difference could be down to the difference in passage number of the C8161 cells. It was 
noted that in Chapter 4.1 – Figure 14, C8161 were lysed whilst at a low passage number 
(passage 10) and in Chapter 4.1 – Figure 15, were lysed whilst at a high passage (passage 27). 
This remains to be confirmed by direct comparison between C8161 cells at different passage 
numbers but this could suggest that PDILT is induced in melanoma tissue in situ, but fades in 
vitro over time. However, whilst PDILT expression in these melanoma cell lines remains 
inconclusive, analysis with a CLGN antibody revealed that CLGN was definitely expressed in 
the C8161 cell line. CLGN is also an ER resident protein that was identified as a key mediator 
of spermatogenesis. Rats immunized to testis cells had the resultant antibodies purified and 
used to identify different proteins involved in the male reproductive process (Watanabe et 
al. 1993). This led to the characterisation of CLGN and further work in mice identified that 
CLGN -/- sperm both failed to bind to the membrane of the zona pellucida or migrate into 
the oviduct (Ikawa et al. 2001). This protein also has been linked to certain cancers, for 
example CLGN has been suggested to be expressed in breast cancer following bone 
metastasis (Smid et al. 2006). Thus the identification of this protein in C8161 cells is novel 
but logical. When probing the melanoma cell lysates with the CNX antibody all cell lines 
tested showed expression of CNX, which is to be expected given the universal expression of 
the protein across all cell types. So whilst PDILT does not appear to be expressed in the 
majority of melanoma cell lines, it does appear that CLGN is expressed in the C8161 cell line.  
The observation that the C8161 cell line expresses CLGN was confirmed by immunoblotting 
with a commercially available antibody (Chapter 4.1 – Figure 16). To further explore the 
expression of CLGN and other ER proteins, a series of immunofluorescence experiments 
were carried out on C8161 cells (Chapter 4.2 – Figure 17). C8161 did show staining for CLGN 
in a perinuclear location. This suggests that CLGN is localised to the ER of the C8161 cells, 
but a more extensive colocalisation study with a range of known ER proteins would help to 
extend these observations. The lack of PDILT staining in the C8161 cell line suggests that 
either PDILT is not expressed in this melanoma, or there is passage dependent 
downregulation of PDILT expression when cells are cultured. 
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Following on from the observation that the C8161 cell line expresses CLGN, it was then 
investigated to see if CLGN expression was specific to the C8161 cell line or if this expression 
was linked to the genetic profile of the C8161 cell line. One of the most frequent mutations 
in melanoma is a V600E mutation occurring in BRAF, a serine/threonine kinase protein 
involved in the MAP signalling cascade, with a mutation occurring in this protein in 50 % of 
melanoma (Ascierto et al. 2012). This signalling cascade is shown in Figure 23. The C8161 cell 
line was the only cell line to have a wild type form of BRAF and NRAS. In order to test if other 
melanoma cell lines with this genetic profile also express CLGN, CHL1 cells were also tested 
for CLGN expression and found to be CLGN positive (Chapter 4.2 – Figure 18). This suggests 
that melanoma cell lines that maintain a WT BRAF and a WT NRAS during their cancer 
progression express CLGN. Two melanocyte cell types were assessed to ascertain whether 
CLGN expression is gained or lost following cancerous transformation. Neither the lightly 
pigmented nor the heavily pigmented melanocyte lysates showed a positive result for CLGN 
expression, demonstrating that CLGN expression occurs post melanocyte transformation. 
This is potentially significant as it has been noted that unlike melanomas carrying mutations 
in BRAF, which are treatable with drugs such as vemurafenib (Sosman et al. 2012) or 
dabrafenib (Hauschild et al. 2012), WT BRAF melanomas are refractory to current drug 
treatments. Thus, evidence that WT BRAF melanoma cell lines express a novel ER resident 
chaperone protein, post transformation, lays the ground work for exploring CLGN (or its 
clients) as a possible therapeutic target. However, before this can be done, a more extensive 
analysis of the contribution of this protein to maintaining or contributing to cancer cell 
fitness has to be conducted.  The key factors to assess are whether CLGN contributes to the 
proliferation, migration, cell survival or metastasis of cancer cells. Given that CLGN is an ER 
protein involved in protein folding, it is likely that its upregulation could enhance the 
secretion of other proteins (such as growth factors or adhesion molecules) involved in these 
processes. Thus, it is possible that manipulating the expression or activity of CLGN could 








Figure 23. The MAP signalling cascade with WT BRAF and V600E BRAF. Under normal 
signalling conditions, growth factors such as EGF bind to the EGF receptor, which causes 
phosphorylation on its tyrosine residues. That allows GRB2 and SOS to bind in a complex to 
the EGFR. SOS becomes activated which allows Ras to bind to the complex. This causes the 
GDP bound to Ras to dissociate, allowing GTP to bind to it, which then activates Ras. 
Activated Ras can activate MEK, which then activates ERK. This signal transduction cascade 
causes the induction of genes involved in cell survival and proliferation. An issue arises when 
BRAF has a V600E mutation, which causes the protein to be constitutively active, leading to 



























5.4 Impact of Spheroid Morphology and Hypoxia on CLGN Expression 
Having established the expression of CLGN in WT BRAF melanoma cell lines, the impact of a 
variety of factors on the expression of CLGN and other proteins was also explored. Two 
factors were analysed, namely 3D cell culture and hypoxia. Cells were grown as spheroids, as 
this 3D cellular arrangement encourages the development of a necrotic core due to the lack 
of an oxygen supply. C8161 spheroids were either analysed by western blotting (Chapter 4.3 
– Figure 19) or imbedded into paraffin and subject to immunofluorescence (Chapter 4.3 – 
Figure 20 and 21). 
Initial immunofluorescence of the spheroids revealed CGLN expression within the C8161 
spheroids (Chapter 4.3 – Figure 20). In the C8161 spheroids there appeared to be some 
staining at the periphery of the outer cells, which was absent in the WM164 spheroids 
(Chapter 4.3 – Figure 21). It is possible that a combination of pro-survival signals secreted by 
the cell and pro-apoptotic signals from the necrotic core promotes CLGN expression. 
Unexpectedly, both the C8161 and WM164 spheroids appeared to show PDILT staining at 
the exterior of spheroid cells. This is most likely due to edge effects or secondary antibody 
staining and could be resolved using alternative PDILT antibody staining strategies. 
Spheroids did not, at any time point, show any protein expression of PDILT. Thus, neither 3D 
arrangement of cells or hypoxic pressure from the necrotic core was able to induce the 
expression of PDILT. When the same spheroid lysates were blotted with the CLGN antibody, 
the C8161 spheroids showed consistent CLGN staining across all time points. This shows that 
neither 3D structure nor increasing hypoxic pressure alters the level of expression of CLGN. 
The CLGN negative WM164 cell line showed no expression of CLGN at any point when grown 
as spheroids. This demonstrates that neither 3D structure nor hypoxic pressure from the 
necrotic core was able to induce CLGN expression and was not able to alter the level of 
expression of the protein. This could be because the cell already expresses CLGN at the 
highest level. However, the level of hypoxia at the centre of each spheroid was not verified 
in these experiments. To further explore the effects of hypoxia, the spheroids could be 
stained for known markers of hypoxia, such as HIF1alpha. Alternatively, spheroids could be 
incubated in a hypoxic chamber for a predetermined amount of time and then analysed. 
Little is known about how the transcription of CLGN (and PDILT) is regulated in the testis. 
Thus it would also be informative to conduct promoter binding studies and perform 




5.5 Calmegin Expression in Human Melanoma Tumours 
Whilst the observation that CLGN is expressed in WT BRAF melanoma cell lines is of note, it 
is important to demonstrate whether this expression also occurs in human WT BRAF 
tumours, to realise any therapeutic potential of targeting this protein. Thus several human 
melanoma tumours were initially screened for CLGN and PDILT expression (Chapter 4.4 – 
Figure 22). Unfortunately, the preliminary results from this analysis were inconclusive 
because of incomplete antigen retrieval. Some staining was apparent in some of the 
sections, but appeared to be nonspecific as a result of edge effects. Thus, a full optimization 
of antigen retrieval should be carried out on a variety of human tumours to ensure that 
antigen retrieval is complete. Co-staining the tissue with a known melanoma marker, such as 
Melan A, would ensure that any positive staining for CLGN or PDILT could be co-localised 
with cancerous tissue.  
5.6 Future Work 
In this thesis, I have focused on two areas of investigation. The first was an analysis of how 
different structural elements of PDILT contribute to PDILTs client binding. This led to the 
theory that the C terminal tail of PDILT, which is extended in comparison to other proteins in 
the same family, regulates the interactions between PDILT and its client proteins. This 
suggested mechanism of action is consistent with the recently published crystal structures of 
PDILT (Yang et al. 2018) and should be further explored in future work.  
One possible way of exploring this theory is to co-transfect cells with PDILT DEL 498-589 or 
PDILT DEL 520-580 mutants with constructs bearing their missing tail peptides. If increased 
expression/concentration of the tail fragment protein causes a decrease in the high 
molecular weight complexes forming (which could be tested by the western blotting method 
outlined in Chapter 3.2 – Figure 9), this would provide further evidence that the tail 
regulates client binding. Similar studies could be performed using an in vitro translation 
approach. Putative regulation could also be confirmed by carrying out quantitative mass 
spectrometry, and comparing the number of interactions with the PDILT tail deleted 
mutants to the number of protein interactions with the WT PDILTs. That would provide 
further quantitative proof that an increase in client interactions occurs and would add to the 
qualitative data provided by the western blots. It would also be interesting to assess 
whether there are any particular types of proteins (in terms of function or structural 
characteristics) that have increased binding compared to others when the tail is removed. 
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The second area of investigation conducted in this thesis examined whether melanoma cells 
express PDILT or CLGN. This thesis suggests that PDILT is probably not expressed in the 
tested melanoma cell lines, but has demonstrated that CLGN is expressed in melanoma cell 
lines that maintain a WT form of BRAF. This unique protein expression in this form of 
melanoma could be exploited therapeutically, as disrupting the function of CLGN within the 
cancer cell could lead to increased ER stress and ultimately apoptosis of the cell. 
However, before the therapeutic potential of CLGN can be realised, a full understanding of 
how CLGN expression supports cancer cell growth must be understood. Future work should 
be focused on knocking out CLGN and analysing if this impacts on a variety of cancer 
activities, such as proliferation, migration and metastasis. It is possible that CLGN 
contributes to these cancerous activities indirectly, through ensuring the correct folding of 
other proteins involved in these processes. Cancers are able to upregulate proteins involved 
in proliferation, migration and cell survival but without ensuring these proteins can be 
correctly folded and trafficked, this would ultimately lead to increased ER stress and trigger 
UPR induced cell death. Thus, it is possible that CLGN could contribute to one or more of 
these cancerous activities, by ensuring particular client proteins are correctly folded.  The 
impact of knocking down CLGN on proliferation could be analysed with a combination of 
MTT and MTS assays. The impact on migration could be analysed with the use of a collagen 
cell invasion assay or could be performed on skin equivalent models to understand the 
invasion in a more appropriate environment. Once these knockdown effects have been 
observed, targeting the protein with a variety of possible therapeutics can begin. However, 
another important area requiring research is the exact mechanism by which genes, such as 
CLGN, become derepressed during melanoma development. A combination of promoter 
binding studies and chromatin immunoprecipitation assays (ChiP) would begin to elucidate 
this process.  
Work also needs to be performed to validate the expression of CLGN in human WT BRAF 
melanoma tumours, to ensure that results in the cell lines can be translated into patients.  
5.7 Conclusion 
In this thesis, the role of key structural elements of PDILT in facilitating client binding and the 
expression of PDILT and CLGN in melanoma cells has been explored.  
This thesis has expanded on the work initially performed by van Lith and Benham 2007, 
exploring the role the cysteines and the C-terminal extension play in PDILTs ability to bind to 
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client proteins. It has added further evidence to the importance of the solvent-exposed 
cysteines present in PDILT in mediating disulphide based interactions with potential client 
proteins and also theorised on the role of the C-terminal extension. Our hypothesis is that 
the C-terminal extension regulates interactions between client proteins and PDILT. This 
additional knowledge of PDILT is important and this will hopefully lead to a more complete 
understanding of the molecular mechanisms of PDILT that underpin its role in male fertility, 
and may help us to understand how PDILT interacts with the sperm:egg binding protein 
ADAM3.  
This thesis also explored the possibility that testis-specific ER chaperones are expressed in 
melanoma cells. The thesis has clearly shown that CLGN is expressed in the ER of melanoma 
cell lines that maintain a wild type form of BRAF and NRAS. This is potentially significant as 
current treatments of melanoma have shown to have limited long term efficacy (Flaherty et 
al. 2012). This is especially true in terms of treating melanomas that maintain a WT BRAF, as 
they currently lack any targeted treatment. Thus, further work proving CLGN expression in 
WT BRAF human melanoma tumours would open the possible therapeutic option of 
targeting this protein to induce UPR mediated apoptosis, which has already been 
demonstrated to be effective when targeting PDI (Lovat et al. 2008). However, the 
expression of CLGN in human melanoma needs to be validated in future. This previous work 
has demonstrated the effectiveness of targeting ER disulfide-isomerases as a melanoma 
treatment, but targeting other forms of ER processing such as the complex mechanism of 
glycosylation, have yet to be investigated as possible melanoma treatments. This approach 
could be built around further knowledge of the molecular mechanisms that allow melanoma 
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